



# Inter-correlations Among Clinical, Metabolic, and Biochemical Parameters and Their Predictive Value in Healthy and Overtrained Male Athletes: The EROS-CORRELATIONS Study

#### Flavio A. Cadegiani\* and Claudio E. Kater

Adrenal and Hypertension Unit, Division of Endocrinology and Metabolism, Department of Medicine, Federal University of São Paulo Medical School, São Paulo, Brazil

#### **OPEN ACCESS**

Edited by: Katia Collomp, University of Orléans, France

#### Reviewed by:

Jean-Frédéric Brun, INSERM U1046 Physiologie et médecine expérimentale du coeur et des muscles, France Guillaume Py, Université de Montpellier, France

#### \*Correspondence:

Flavio A. Cadegiani superendocrinology@gmail.com; flavio.cadegiani@unifesp.br

#### Specialty section:

This article was submitted to Translational Endocrinology, a section of the journal Frontiers in Endocrinology

Received: 30 May 2019 Accepted: 22 November 2019 Published: 10 December 2019

#### Citation:

Cadegiani FA and Kater CE (2019) Inter-correlations Among Clinical, Metabolic, and Biochemical Parameters and Their Predictive Value in Healthy and Overtrained Male Athletes: The EROS-CORRELATIONS Study. Front. Endocrinol. 10:858. doi: 10.3389/fendo.2019.00858 **Objectives:** The Endocrine and Metabolic Responses on Overtraining Syndrome (EROS) study identified multiple hormonal and metabolic conditioning processes in athletes, and underlying mechanisms and biomarkers of overtraining syndrome (OTS). The present study's objective was to reveal independent predictors and linear correlations among the parameters evaluated in the EROS study to predict clinical, metabolic, and biochemical behaviors in healthy and OTS-affected male athletes.

**Methods:** We used multivariate linear regression and linear correlation to analyze possible combinations of the 38 parameters evaluated in the EROS study that revealed significant differences between healthy and OTS-affected athletes.

**Results:** The testosterone-to-estradiol (T:E) ratio predicted the measured-to-predicted basal metabolic rate (BMR) ratio; the T:E ratio and total testosterone level were inversely predicted by fat mass and estradiol was not predicted by any of the non-modifiable parameters. Early and late growth hormone, cortisol, and prolactin responses to an insulin tolerance test (ITT) were strongly correlated. Hormonal responses to the ITT were positively correlated with fat oxidation, predicted-to-measured BMR ratio, muscle mass, and vigor, and inversely correlated with fat mass and fatigue. Salivary cortisol 30 min after awakening and the T:E ratio were inversely correlated with fatigue. Tension was inversely correlated with libido and directly correlated with body fat. The predicted-to-measured BMR ratio was correlated with muscle mass and body water, while fat oxidation was directly correlated with body water, and extracellular water was directly correlated with body fat and inversely correlated with body water and muscle mass.

**Conclusions:** Hypothalamic-pituitary responses to stimulation were diffuse and indistinguishable between the different axes. A late hormonal response to stimulation, increased cortisol after awakening, and the T:E ratio were correlated with vigor and

1

fatigue. The T:E ratio was also correlated with body metabolism and composition, testosterone was predicted by fat mass, and estradiol predicted anger. Hydration status was inversely correlated with edema, and inter-correlations were found among fat oxidation, hydration, and body fat.

Keywords: hormonal conditioning, endocrinology of physical activity, sports endocrinology, hormones and sports, endocrine and metabolic responses on overtraining syndrome (EROS) study, overtraining syndrome

#### INTRODUCTION

The benefits of extensive exercise have exceeded previous expectations, including primary prevention, active part of the treatment, improvement of life quality, and prognosis under chronic or incurable diseases, and prevention of complications and recurrence, of a wide range of diseases, including cardiovascular (1, 2), hypertension, type 2 diabetes mellitus (T2DM) (1), dyslipidemia, cancers (3–6), cognitive function (7), and all quality of life domains (8–10).

Many of the benefits from physical activity are linked to multiple adaptive changes that leads to improvements in neuromuscular (11), cardiovascular (12), musculoskeletal, autonomic, and other systems that active individuals undergo. However, these benefits may only occur when physically active individuals sleep and eat appropriately, alongside with training (13, 14).

Indeed, overtraining syndrome (OTS), which affects between 40 and 60% of the elite athletes during their careers, is likely a major manifestation of the harms of an imbalance between excessive training, insufficient recovery, non-refreshing sleep, insufficient caloric, protein, and/or carbohydrate intake, and concurrent psychological stress, including excessive cognitive effort, social, familiar, or financial issues (15–17). This imbalance is the likely underlying reason of the paradoxical loss of physical performance in OTS, which is not able to be justified by any apparent dysfunction (15). However, OTS is still a controversial issue since several characteristics of OTS, including underlying mechanisms, pathophysiology, and biological markers are universally accepted or clarified, as the prevailing findings on previous studies were inconsistent (15–17).

To address all the unanswered questions on OTS, and also to better understand the multiple conditioning processes that athletes seem to undergo, we conducted the Endocrine and Metabolic Responses to Overtraining Syndrome (EROS) study (18–24). In that study, we evaluated basal and exerciseindependent hormonal responses to stimulation tests, multiple biochemical markers, including muscular, inflammatory, immunologic, and nutritional parameters, specific eating, psychological, and social patterns, and the body metabolism and composition of healthy athletes, athletes affected by OTS, and sedentary individuals with similar baseline characteristics (age, sex, and body mass index—BMI). The list of parameters evaluated by the EROS study are detailed in **Table 1**, together with the selection process for the present analysis, to be described further. Among the 117 markers evaluated in the EROS study, we identified 50 novel parameters for OTS-affected and healthy athletes, including amplified and prolonged GH, cortisol, and prolactin responses to a stimulation test, increased testosterone, lactate clearance, catecholamines, basal metabolic rate (BMR), fat oxidation, and hydration in healthy athletes, and blunted hormonal responses (compared to healthy athletes), increased creatine kinase (CK), aromatase activity, estradiol, anger, depression, fatigue, mental confusion and fat mass, and reduced testosterone, hydration, muscle mass, BMR, fat oxidation, and moods in athletes affected by OTS (23). The major findings of the EROS study are described in **Figure 1**.

The findings unveiled by the EROS study supported the hypothesis of the existence of multiple adaptations of clinical, metabolic, biochemical, and body parameters that athletes, while the majority of the physiological adaptive changes are compromised in OTS, which may explain the hallmark of OTS, the loss of performance (23, 24).

Despite the multiple and broad adaptive changes previously demonstrated to occur in athletes, and the more than 50 novel markers and processes identified in both healthy and OTSaffected athletes in the present study, the relationships between parameters that are affected by training and/or OTS are unclear (18–21). Associations, interactions, synergisms, stimulations, and inhibitions between hormones, inflammatory, immunologic, muscular, metabolic, and clinical markers, and psychological, eating, sleep, and training patterns, have been poorly assessed previously, and have not been identified in the EROS study, once our primary objective was to detect differences between OTS and healthy athletes, and sedentary control among the 117 parameters evaluated, using three-group and pairwise comparisons, which were published in different arms (18–24).

The unexpected large number of markers identified in both populations of athletes allowed us hypothesize the existence of a web of multiple sorts of interactions between parameters of different natures, which could result in the wide range of benefits and improved performance observed in healthy athletes, and the paradoxical decrease of sports performance, fatigue, reduced libido, and body changes in OTS (24). The correlations to be identified between the newly uncovered parameters could provide a new understanding of the complex processes of conditioning processes that athletes typically undergo, and the convoluted mechanisms that lead to OTS (23, 24).

In summary, despite the large number of discoveries (18– 22, 24), our primary findings do not demonstrate the multiple sorts of relationship between those markers that participate in the adaptative processes of the athletes and those that have

#### TABLE 1 | Eligible markers for the present analysis.

Tests	Markers	Initially elected? (Provide independent data, provide additional data (in relation to other parameters evaluated), substantiated/validated)	Significantly different between OTS-affected and healthy athletes? (If "Yes," included in the present analysis)
BASAL BIOCHEMICAL TES	STS		
Basal hormones	<ol> <li>Total testosterone (ng/dL)</li> <li>Estradiol (pg/mL)</li> <li>IGF-1 (pg/mL)</li> <li>TSH (μUl/mL)</li> <li>Free T3 (pg/mL)</li> <li>Total catecholamines (μg/12 h)</li> <li>Total metanephrines (μg/12 h)</li> </ol>	Yes Yes Yes Yes Yes Yes	Yes Yes No No Yes No
Muscular inflammatory	<ul> <li>(8) Noradrenaline (μg/12 h)</li> <li>(9) Epinephrine (μg/12 h)</li> <li>(10) Dopamine (μg/12 h)</li> <li>(11) Metanephrines (μg/12 h)</li> <li>(12) Normetanephrines (μg/12 h)</li> <li>(13) Enthrocyte sedimentation rate</li> </ul>	Yes Yes Yes Yes Yes	No No <b>Yes</b> No No
immunologic, and other basal biochemical markers	<ul> <li>(To) Lytamor be obtained table table</li> <li>(ESR, mm/h)</li> <li>(14) Hematocrit (%)</li> <li>(15) C-reactive protein (CRP, mg/dL)</li> <li>(16) Lactate (nMol/L)</li> <li>(17) Vitamin B12 (pg/mL)</li> <li>(18) Ferritin (ng/mL)</li> <li>(19) Neutrophils (mm<sup>3</sup>)</li> <li>(20) Lymphocyte (mm<sup>3</sup>)</li> <li>(21) Eosinophils (mm<sup>3</sup>)</li> <li>(22) Creatine kinase (CK, U/L)</li> <li>(23) Low-density lipoprotein cholesterol</li> <li>(LDLc, mg/dL)</li> <li>(24) High-density lipoprotein cholesterol</li> <li>(HDLc, mg/dL)</li> <li>(25) Tryglycerides (mg/dL)</li> <li>(26) Medium corpuscular volume (MCV)</li> <li>(27) Platelets (10<sup>3</sup>/mm)</li> </ul>	Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes	No No Yes No Yes Yes* No Yes No No No
Ratios	<ul> <li>(28) Testosterone-to-oestradiol ratio</li> <li>(29) Testosterone-to-cortisol ratio</li> <li>(30) Neutrophil-to-lymphocyte ratio</li> <li>(31) Platelet-to-lymphocyte ratio</li> <li>(32) Catecholamine-to- metanephrine ratio</li> </ul>	Yes Yes Yes No (Non-validated marker)	Yes No Yes Yes*
HORMONAL FUNCTIONAL	TESTS		
Insulin tolerance test (ITT)	<ul> <li>(33) Basal ACTH (pg/mL)</li> <li>(34) ACTH during</li> <li>hypoglycaemia (pg/mL)</li> <li>(35) ACTH 30 min after</li> <li>hypoglycemia (pg/mL)</li> </ul>	Yes Yes	No No Yes
	<ul> <li>(36) ACTH increase during ITT (pg/mL)</li> <li>(37) Basal cortisol (μg/dL)</li> <li>(38) Cortisol during</li> <li>hypoglycaemia (μg/dL)</li> <li>(39) Cortisol 30 min after</li> <li>hypoglycaemia (μg/dL)</li> </ul>	Yes Yes Yes	Yes No Yes
	<ul> <li>(40) Cortisol increase during ITT (μg/dL)</li> <li>(41) Basal GH (μg/L)</li> <li>(42) GH during hypoglycaemia (μg/L)</li> <li>(43) GH 30 min after</li> <li>hypoglycemia (μg/L)</li> </ul>	Yes Yes Yes Yes	No Yes Yes Yes
	<ul> <li>(44) Basal prolactin (ng/mL)</li> <li>(45) Prolactin during</li> <li>hypoglycaemia (ng/mL)</li> <li>(46) Prolactin 30 min after</li> <li>hypoglycemia (ng/mL)</li> </ul>	Yes Yes	Yes Yes

(Continued)

#### TABLE 1 | Continued

Key Production charging during (TT (ng/mL)) (49) Production charging during (TT (ng/mL)) (49) ACT Microthic of the 0: 0000         Yes         No.           ACT Microthic of the 0: 0000         No. (Non-widdlated marker)         -           ACT Microthic of the 0: 0000         No. (Non-widdlated marker)         -           ACT Microthic of the 0: 0000         No. (Non-widdlated marker)         -           ACT Microthic of the 0: 0000         No. (Non-widdlated marker)         -           ACT Microthic of the 0: 0000         No. (Non-widdlated marker)         -           ACT Microthic of the 0: 0000         No. (Alces and provide useful data)         -           Disp. Ammenge complexations during Thropolycomic (hg/dt)         No. (Alces and provide useful data)         -           Disp. Ammenge complexations during Thropolycomic (hg/dt)         No. (Alces and provide useful data)         -           Disp. Ammenge complexations during Thropolycomic (hg/dt)         No. (Alces and provide useful data)         -           Disp. Ammenge complexations during Thropolycomic (hg/dt)         No. (Anon-waldlated marker)         -           Disp. Ammenge complexations during Thropolycomic (hg/dt)         No. (Anon-waldlated marker)         -           Disp. Ammenge complexations during Thropolycomic (hg/dt)         No. (Anon-waldlated marker)         -           Disp. Ammenge complexation during (hg/dt)         Yes <td< th=""><th>Tests</th><th>Markers</th><th>Initially elected? (Provide independent data, provide additional data (in relation to other parameters evaluated), substantiated/validated)</th><th>Significantly different between OTS-affected and healthy athletes? (If "Yes," included in the present analysis)</th></td<>	Tests	Markers	Initially elected? (Provide independent data, provide additional data (in relation to other parameters evaluated), substantiated/validated)	Significantly different between OTS-affected and healthy athletes? (If "Yes," included in the present analysis)
(4) Baak ACT+Contact main         No (Non-wildlader marker)         -           (4) ACT+Contact and in the Non-wildlader marker)         -           (5) MacT+Contact and in Sum         No (Non-wildlader marker)         -           (5) MacT+Contact and in Sum         No (Non-wildlader marker)         -           (5) MacT+Contact and in Sum         No (Non-wildlader marker)         -           (5) Bast sum glucose during         No (Non-wildlader marker)         -           (5) Capting glucose during         No (Non-wildlader marker)         -           (5) Capting glucose during         No (Non-wildlader marker)         -           (5) Samp (glucose)         No (Non-wildlader marker)         -           (5) Capting (glucose)         No (Non-wildlader marker)         -           (5) Samp (glucose)         No (Non-wildlader marker)         -           (5) Caption (Glucose)         No (Non-wildlader marker)         -           (5) Caption (Glucose control no (Glucose)         No (Glucose)         No           (5) Caption (Glucose)         No (Glucose)         No         No           (5) Caption (Glucose)         No (Glucose)         No         No           (5) Caption (Glucose)         No         No         No           (5) Caption (Glucose)         No         No <td></td> <td>(47) Prolactin change during ITT (ng/mL)</td> <td>Yes</td> <td>No</td>		(47) Prolactin change during ITT (ng/mL)	Yes	No
		(48) Basal ACTH/cortisol ratio	No (Non-validated marker)	-
diving hypogloams         No         No         No         No           diff hypogloams         No         No         No         No         No           diff hypogloams         No         No </td <td></td> <td>(49) ACTH/cortisol ratio</td> <td>No (Non-validated marker)</td> <td>-</td>		(49) ACTH/cortisol ratio	No (Non-validated marker)	-
B(B) ACTI-Voortied notes 30min         No (Non-waldated marker)         -           B(B) Boald serum glucose (mpdl.)         No (does not proved suchil data)         -           B(B) Boald serum glucose (mpdl.)         No (does not proved suchil data)         -           B(B) Califyer (glucose)         No (does not proved suchil data)         -           B(B) ACTI-No (Horn (Horn Validated marker)         -         -           B(B) ACTI-No (Horn (Horn Validated marker)         -         -           B(B) ACTI-No (Horn Validated marker)         -         -           B(B) ACTI-No (Horn Validated marker)         -         -           Converticion (Horn Validated marker)         -         -           B(B) ACTI-No (Horn Validated marker)         -         -           Converticion (Horn Validated marker)         -         -           B(B) ACTI-No (Horn Validated marker		during hypoglycemia		
after hypoglycamia         No (does not provide useful data)         -           B(2) Sourm glucose during hypoglycamia (mg/clu)         No (does not provide useful data)         -           B(3) Capillary glucose during hypoglycamia (mg/clu)         No (does not provide useful data)         -           B(4) Advancejo: symptoms during hypoglycamia (mg/clu)         No (does not provide useful data)         -           Cosynthepin attimulation (B(3) Reamoglycamic (mg/clu)         No (does not provide useful data)         -           B(3) Reamoglycamic (mg/clu)         No (does not provide useful data)         -           B(3) Reamoglycamic (mg/clu)         No (does not provide additional data)         -           B(3) Reamoglycamic (mg/clu)         No (does not provide additional data)         -           B(2) Reaminat addition after         Yes         No           B(3) Reamy control (mg/clu) at (mg/clu)         Yes         No           Salkary control (mg/clu) at (mg/clu)         Yes         No           B(4) Comery control (mg/clu) at (mg/clu)		(50) ACTH/cortisol ratio 30 min	No (Non-validated marker)	-
(a) I deal secura glucose (mg/cl)     No (does not provide useful idad)     -       (b) Side secura glucose (mg/cl)     No (does not provide useful idad)     -       (b) Gel Mennegic symptoms during hypoglucoma (L-10)     No (Not-validated marker)     -       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     No (Not-validated marker)     -       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     No (Not-validated marker)     -       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     No (Not-validated marker)     -       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     No (Not-validated marker)     -       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     No (non-validated marker)     -       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     No (non-validated marker)     -       (c) Gel Mennegic symptoms during histism (g/cl)     Yes     No       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     Yes     No       (c) Gel Mennegic symptoms during hypoglucoma (L-10)     Yes     No       (c) Gel Mennegic symptoms during histism during hypoglucoma during during (L)     Yes     No       (c) Gel Mennegic symptoms during hypoglucoma during during (L)     Yes     No       (c) Gel Mennegic symptoms during hypoglucoma during during (L)     Yes     No       (c) Gel Mennegic symptoms during hypoglucoma during during (L)     Yes     No <td< td=""><td></td><td>after hypoglycaemia</td><td></td><td></td></td<>		after hypoglycaemia		
Bel/ being glubbe during during         No (base not provide useful data)         -           Bel/ Artisenegic symptoms during hypotylicensis (D-10)         No (base not provide useful data)         -           Conjuntegrin alimidation hypotylicensis (D-10)         No (Non-validated markes)         -           Conjuntegrin alimidation hypotylicensis (D-10)         No (Non-validated markes)         -           Conjuntegrin alimidation (CS3)         (Eg) Rand contrad (µg/dL)         No (base not provide useful data)         -           (S1) Contrad 30 mm after (S1) Sinuary contrad (µg/dL)         Yes         No           (S2) Difference bursen based contrads (µg/dL)         Yes         No           (S3) Difference bursen based contrads (µg/dL)         Yes         No           (S3) Contrad any contrad (µg/dL)         Yes         No           (S3) Difference bursen based contrads (µg/dL)         Yes         No           (S4) Contrad any contrad (µg/dL)         Yes         No           (S3) Difference bursen based contrads (µg/dL)         Yes         No           (S4) Contrad any contrad (µg/dL)         Yes         No           (S5) Difference bursen based and non-No         No (not of the scope of the present study)         No           (S4) Contrad any contrad (µg/dL)         Yes         No         No           (S6) Differenco		(51) Basal serum glucose (mg/dL)	No (does not provide useful data)	-
instantion         instantion         instantion         instantion           instantion         instantion         instantion         instantion           instantion         instantion         instantion         instantion           Construction         instantion         instantion         instantion           Construction         instantion         instantion         instantion           Construction         instantion         instantion         instantion           instantion         instantion		(52) Serum glucose during	No (does not provide useful data)	-
ripognomia (nyoda)         reference interpretent atom           ripognomia (b-10)         No (Non-validated markor)         -           Cosyntropin stimulation         (c5) Naurogino (b-10)         No (Aon-validated markor)         -           Cosyntropin stimulation         (c5) Naurogino (b-10)         No (Aon-validated markor)         -           (c5) Costol at 30 min after         Yea         No         No           (c5) Costol at 30 min after         Yea         No           (c5) Naurogino (g-10)         No (con-validated markor)         -           (c5) Naurogino (g-10)         No (con-validated markor)         -           (c5) Naurogino (g-10)         No (con-validated markor)         -           (c6) Subserv contisol (rg/c1)         Yea         No           (c6) Subserv contisol (rg/c1)         Yea         No           (c1) Subserv contisol (rg/c1)         Yea         No           (c5) Direction to repretent beserve to the present study)         No         No           (c2) Subserv contisol (rg/c1)         Yea		(53) Capillany ducose during	No (does not provide useful data)	
6%3     Aff-servegic performs during hypogleomia (p-10)     No (Non-validated marker)     -       Cosyntropin stimulation (sG) Rearrows (sG)     No (Non-validated marker)     -       Cosyntropin stimulation (sG) Rearrows (sG)     No (Soles not provide additional data)     -       (SG) Cortisol at 20 min after intusion (g/cL)     No (Soles not provide additional data)     -       (SG) Cortisol at 20 min after intusion (g/cL)     Yes     No       (SG) Difference between basal cortisol or (sG) Soles cortisol (rg/cL)     No (non-validated marker)     No       Salivary cortisol (rg/cL)     Yes     No     No       Salivary cortisol (rg/cL)     Yes     No     No       (SG) Difference between basal cortisol (rg/LL) at 1 m.     Yes     No     No       (SG) Salivary cortisol (rg/cL) at 1 m.     Yes     No     No       (SG) Proference between basal cortisol (rg/cL) at 1 m.     Yes     No     No       (SG) Proference between basal cortisol (rg/cL) at 1 m.     Yes     No     No       (SG) Proference between basal cortisol (rg/cL) at 1 m.     Yes     No     No       (SG) Proference between basal cortisol (rg/cL) at 1 m.     Yes     No     No       (SG) Proference between basal cortisol (rg/cL) at 1 m.     Yes     No     No       (SG) Proference between basal cortisol (rg/cL) at 1 m.     Yes     No     No<		hypoglycemia (mg/dL)		
Typeopleomia (b-10)         Technologic context (b-2)           Cosyntropin stimulation (SS) Neuropycoopenic symptome during typeopleomia (b-10)         No (Non-validated marker)         -           Cosyntropin stimulation (SS) Control at SOmin after intuisor (g-4)(1) (SS) Control at SOmin after (SS) (SS)         Yes         No           Salivary control (g-10) (SS) Control at SOmin after intuisor (g-4)(1) (SS) Control at SOmin after (SS) Salivary control (g-10)(1) (SS) Salivary control		(54) Adreneraic symptoms during	No (Non-validated marker)	-
(5) Naurogicogenic symptoms during hypothema (J-1)No (khow-validated marker)-Cosyntrepin stimulation test (CST)(56) Basal cortisol (µ,q/cl.)No (khow not provide additional data)-(57) Cortisol at 30 min after hasion (µ,g/cl.)YesNo(58) Cortisol at 00 min after hasion (µ,g/cl.)YesNo(59) Difference between basal cortisol on ad valceningNo (non-validated marker)-(59) Saliway cortisol (µ,g/cl.)YesNoSaliway cortisol (µ,g/cl.)YesNo(59) Saliway cortisol (µ,g/cl.)YesNo(60) Saliway cortisol (µ,g/cl.)YesNo(61) Saliway cortisol (µ,g/cl.)YesNo(62) Saliway cortisol (µ,g/cl.)YesNo(63) Saliway cortisol (µ,g/cl.)YesNo(64) Cortisol awakening response (CAPI) (No (unot the scope of the present study)No(64) Cortisol awakening response (CAPI) (No (qualtative marker))YesNo(70) Initial immonia (Y/N)No (qualtative marker)-(71) Minial immonia (Y/N)No (qualtative marker)-(72) More than two wake-ups during (73) Work and/or study (Y/N)No (qualtative marker)-(71) Minial immonia (Y/N)No (qualtative marker)-(72) Garbordydrate intake (g/kg/dsy)No (qualtative marker)-(73) Work and/or study (Y/N)No (qualtative marker)-(74) Minia (marker)No (qualtative marker)-(75) Carbordydrate intake (g/kg/dsy)No (qualtative marker)-(76)		hypoglicemia (0–10)		
hypoglicemia (-10)         No           Cosyntropic stimulation         (56) Seasio ontiool (µ,g/d1)         No           (15) Contiool at 20 min after         Yes         No           (15) Contiool (15) (min after         Yes         No           (16) Obtained (µ,g/d1)         (17) (No         No           (16) Obtained (17) (GN)         (10) (non-validated marker)         -           (27) Obtained (17) (GN)         (10) (non-validated marker)         -           (28) Contisol (17) (GN)         Yes         No           (20) Sinvary contisol (ng/d1) (21 4 p.m.)         Yes         No           (28) Sinvary contisol (ng/d1) (21 4 p.m.)         Yes         No           (26) Sinvary contisol (ng/d1) (21 4 p.m.)         Yes         No           (26) Sinvary contisol (ng/d1) (21 4 p.m.)         Yes         No           (26) Obtaineroo between Sam. and -         No (non-validated marker)         -           (27) Minetro fiburatio and rading time (PM)         Yes         No           (28) Difference between Sam. and -         No (non the scope of the present study)         No           (28) Sinvary contisol (ND)         No (qualitative marker)         -         -           (21) Cost-dividated caltriding precide / No         No (qualitative marker)         -         - </td <td></td> <td>(55) Neuroglycopenic symptoms during</td> <td>No (Non-validated marker)</td> <td>-</td>		(55) Neuroglycopenic symptoms during	No (Non-validated marker)	-
Cosyntropins stimulation (65) Elsaid critical (ug/dL)     No (loses not provide additional data)     -       test (CST)     (CST)     Yes     No       (60) Consist at 30 min after indusion (ug/dL)     Yes     No       (61) Consist at 30 min after indusion (ug/dL)     Yes     No       (62) Consist at 30 min after indusion (ug/dL)     Yes     No       (63) Saliway contice (ng/dL)     Yes     No       (64) Saliway contice (ng/dL) at 14 p.m.     Yes     No       (63) Saliway contice (ng/dL) at 14 p.m.     Yes     No       (64) Contised advaluence status     No     No       (65) Saliway contice (ng/dL) at 14 p.m.     Yes     No       (64) Contised advaluence status     No     No     No       (65) Saliway contice (ng/dL) at 14 p.m.     Yes     No     No       (65) Saliway contice (ng/dL) at 14 p.m.     Yes     No     No       (64) Contised advaluence status     No     No     No       (65) Saliway contice (ng/dL) at 14 p.m.     Yes     No     No       (64) Contised advaluence status     No     No     No     No       (65) Saliway contice (ng/dL) at 14 p.m.     Yes     No     No       (64) Contised advaluence status     No     No     No     No       (71) Terminal Innosonic (NA)     No (adval		hypoglicemia (0–10)		
test (CS1)         (F)         Contrast at 20min after intuision (µ,d/L)         Yes         No           (S9)         Ottersion after intuision (µ,d/L)         Yes         No           (S9)         Difference between based oortisel on day 1 (CS1) and day 3 (TT) (%)         No (non-validated marker)         -           Salivary control (hy/th)         (S0)         Yes         No           (S0)         Salivary control (hy/th)         Yes         No           (S1)         Salivary control (hy/th)         Yes         No           (S2)         Salivary control (hy/th)         Yes         No           (S3)         Salivary control (hy/th)         Yes         No           (S2)         Salivary control (hy/th)         Yes         No           (S3)         Salivary control (hy/th)         Yes         No           (S4)         Dutation of hight skep (hinght)         Yes         No           (S3)         Self-sported libido (D-10)         Yes         No           (S4)         Dutation of hight skep (hinght)         Yes         No           (S4)         Dutation of hight skep (hinght)         No (qualitative marker)         -           (S4)         Self-sported libido (D-10)         Yes         No           (S	Cosyntropin stimulation	(56) Basal cortisol (μg/dL)	No (does not provide additional data)	-
inflution (u.g.dL)     No       (SP) Cortisol at 60 min after influion (u.g.dL)     No (non-validated marker)     No       (SP) Difference between basal cortisol on (sty 1 (ST)) and (alg 3 (TT) (%)     No (non-validated marker)     No       Sativary cortisol (ng/dL)     Yes     No       (SP) Difference between basal cortisol on (ng 1 (SR)) and (alg 3 (TT) (%)     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (ng/dL) at 1 p.m.     Yes     No       (SP) Sativary cortisol (N/N)     No (cualitative marker)     No       (SP) Sativary cortisol (N/N)     No (cualitative marker)     -       (SP) More in Instance (u.gl/dg/da)     No (cualitative marker)     - <td< td=""><td>test (CST)</td><td>(57) Cortisol at 30 min after</td><td>Yes</td><td>No</td></td<>	test (CST)	(57) Cortisol at 30 min after	Yes	No
(68) Contisol at 00 min after in fusion: (GSD) Difference between basic locitical on day 1 (GSD) and day 3 (TT) (%)No (non-validated marker)No cons-validated marker)NoSalivary contisol (ng/CL) at availening (GSD) Salivary contisol (ng/CL) 30 min after availening (GSD) Salivary contisol (ng/CL) 11 (1 p.m.) (GSD) Difference between 8 a.m. and (GSD) Difference between 8 a.m. and (GSD) Difference between 9 a.m. and (CSD) Difference 1 p.m. salivary cortisol (%)No (cout of the scope of the present study) (CSD) Difference 1 p.m. salivary cortisol (%)No (cout of the scope of the present study) (CSD) Difference 1 p.m. and minor 10 (MD) (CSD) Difference 1 p.m. and 10 (MD) (CSD) Difference 1		infusion (μg/dL)		
intusion (g.q/L) (g. D)Efference between basel cortision (g. q. (C.S.T) and day 3 (IT) (%)No (Monormal dated marker)-Salivary cortisol (ng/dL)YesNo(SCP)(G.S. Salivary cortisol (ng/dL) 30 min (g.S. Salivary cortisol (ng/dL) 4 p.m. (g.S. Salivary cortisol (ng/dL) (d.S. Salivary cortisol (ng/dL) 4 p.m. (g.S. Salivary cortisol (ng/dL) (d.S.		(58) Cortisol at 60 min after	Yes	No
(5)     Difference between basel cortisol on (H1 CST) and days (HT) (%)     No (non-validated marker)     -       Salivary cortisol (ng/dL)     Yes     No       (SCF)     (B) Salivary cortisol (ng/dL) 30 min after awakening     Yes     Yes       (C) Salivary cortisol (ng/dL) at 1 p.m.     Yes     No       (C) Salivary cortisol (ng/dL) at 1 1 p.m.     Yes     No       (C) Salivary cortisol (ng/dL) at 1 1 p.m.     Yes     No       (C) Cortisol awakening response (CAP)     Yes     No       (C) Salivary cortisol (ng/dL) at 1 1 p.m.     Yes     No       (C) Cortisol awakening response (CAP)     Yes     No       (C) Cortisol awakening response (CAP)     Yes     No       (C) Difference between 8 a.m. and 4     No (non-validated marker)     No       (B) Director of night sleep (hr/night)     Yes     Yes       Christol (R) Salivary cortisol (R)     Yes     Yes       Sleeping and social     (G) Director of night sleep (hr/night)     Yes     Yes       (C) Timinal Immsonia (Y/N)     No (qualitative marker)     -     -       (C) Timinal Immsonia (Y/N)     No (qualitative marker)     -     -       (C) Salivary cortisol (ng/dL) (X)     No (qualitative marker)     -     -       (C) Timinal Immsonia (Y/N)     No (qualitative marker)     -     -		infusion (μg/dL)		
day 1 (CST) and day 3 (TT) (%) (SCP) at awakening (CSP) (Salivay cortisol (ng/dL) 30 min Ves Ves Ves are rawakening (CSP) (ng/dL) 31 4 p.m. Ves No (CSP) Salivary cortisol (ng/dL) 41 p.m. Ves No (CSP) Salivary cortisol (ng/dL) 41 p.m. Ves No (CSP) Cortisol awakening response (CAP) Ves No (CSP) Cortisol of night sleep (h/night) Ves No (CSP) Cortisol (SS) CLINICAL PARAMETERE Sleeping and social (CSP) Sali-reported libido (D-10) Yes Ves No (cut of the scope of the present study) No (CSP) Sali-reported libido (D-10) Yes Ves No (CSP) Sali-reported libido (D-10) Yes Ves No (CSP) Sali-reported libido (D-10) Ves Ves (CSP) Initial immsonia (r/NN) No (qualitative marker) - (CP) Initial immsonia (r/NN) No (qualitative marker) - (CP) Initial immsonia (r/NN) No (qualitative marker) - (CP) More than two wake-ups during sleep (r/N) (CP) Carbority artis (ng/day) No (qualitative marker) - (CP) Cortison from carbority (r/NN) No (qualitative marker) - (CP) Cortison from carbority (r/NN) No (qualitative marker) - (CP) Cortison from carbority (r/NN) No (qualitative marker) - (CP) Carbority artis (ng/day) No (out of the scope of the present study) - (CP) Carbority artis (ng/day) No (out of the scope of the present study) - (CP) Fortein intake (g/kg/day) No (out of the scope of the present study) - (CP) Fortein intake (g/kg/day) No (out of the scope of the present study) and a (CP) Carbority artis (nitake (dr/kg/day) No (out of the scope of the present study) and a (CP) Fortein intake (g/kg/day) No (out of the scope of the present study and a (g/kg/day (r/N)) Qualitative marker) (CP) Fortein intake (g/kg/day) No (out of the scope of the present study and a (g/kg/day (r/N) No (out of the scope of the present s		(59) Difference between basal cortisol on	No (non-validated marker)	-
Salivary cortisol rhythm (60) Salivary cortisol (ng/dL) 30 min (SCP) (61) Salivary cortisol (ng/dL) 30 min (61) Salivary cortisol (ng/dL) 30 min (61) Salivary cortisol (ng/dL) 30 min (62) Salivary cortisol (ng/dL) 41 t1 p.m. (76) (62) Salivary cortisol (ng/dL) 41 t1 p.m. (76) (76) (76) (76) (76) (76) (76) (76)		day 1 (CST) and day 3 (ITT) (%)		
(SCF)       at avakening after avakening (62) Salivary cortisol (ng/dL) at 4 p.m. (63) Salivary cortisol (ng/dL) at 1 p.m. (64) Cortisol avakening response (CAR) (65) Difference between 8 a.m. and 4       Ves       No         (64) Cortisol avakening response (CAR) (65) Difference between 8 a.m. and 4       No (non-validated marker) p.m. salivary cortisol (%)       No         CLINICAL PARAMETERS       (65) Duration of night sleep (t/night)       Yes       No         Sileping and social characteristics       (67) Self-reported libido (D-10)       Yes       No         (68) Sumbor of hours of activities       Yes       No         (70) Initial immsonia (t/N)       No (qualitative marker)       -         (71) Terminal imnsonia (t/N)       No (qualitative marker)       -         (73) Work and/or study (t/N)       No (qualitative marker)       -         (74) Divati immsonia (t/N)       No (qualitative marker)       -         (75) Calorie inflake (kalkg/day)       No (qualitative marker)       -         (76) Carbohydrate intake (g/kg/day)       No (qualitative marker)       -         (77) Work and vor study (t/N)       No (qualitative marker)       -         (76) Carbohydrate intake (g/kg/day)       No (qualitative marker)       -         (77) Work and two wake-ups of the present study)       -       -         (77) Socionies from protein (%)       No	Salivary cortisol rhythm	(60) Salivary cortisol (ng/dL)	Yes	No
(b1) Salkary contisol (ng/dL) 30 min     Yes     Yes       (62) Salkary contisol (ng/dL) at 1 p.m.     Yes     No       (64) Contisol awakening response (CAP)     Yes     No       (65) Difference between 8 a.m. and 4     No (non-validated marker)	(SCR)	at awakening		
anter awarening       results       No         (63) Salivary cortisol (ng/dL) at 1 p.m.       Yes       No         (64) Cortisol awarening response (CAP)       Yes       No         (65) Difference between 8 a.m. and 4       No (non-validated marker)       -         p.m. salivary cortisol (%)       Ves       No         CLINICAL PARAMETERS       (66) Duration of night sleep (h/night)       Yes       No         Sleeping and social       (67) Self-reported isleep quality (U-10)       No (out of the scope of the present study)       No         characteristics       (67) Self-reported isleep quality (U-10)       No (out of the scope of the present study)       No         characteristics       (68) Self-reported isleep quality (U-10)       No (qualitative marker)       -         (70) Initial inmsonia (Y/N)       No (qualitative marker)       -       -         (72) More than two wake-ups during       No (qualitative marker)       -       -         (73) Work and/or study (Y/N)       No (qualitative marker)       -       -         (74) Libido during resting periods /       No (out of the scope of the present study)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)		(61) Salivary cortisol (ng/dL) 30 min	Yes	Yes
(b2) Salavay costsiol (ng/d) at 1 p.m.     Yes     No       (64) Cortisol awakening response (CAR)     Yes     No       (65) Difference between 8 a.m. and 4     No (non-validated marker)     -       p.m. salivary cortisol (%)     Yes     No       CLINICAL PARAMETERS     Sileeping and social     (66) Duration of night sleep (h/night)     Yes     No       Characteristics     (67) Self-reported isolo (0-10)     Yes     Yes     Yes       (68) Selver you control (%)     No (out of the scope of the present study)     No     No       (69) Number of hours of activities     Yes     Yes     Yes       (70) Initial immsonia (Y/N)     No (qualitative marker)     -     -       (71) Terminal immsonia (Y/N)     No (qualitative marker)     -     -       (72) More than two wake-ups during sleep (Yr)     No (qualitative marker)     -     -       (73) Work and/or study (Y/N)     No (qualitative marker)     -     -       (74) Libdo during resting periods /     No (out of the scope of the present study)     -     -       (75) Calorie intake (g/kg/day)     No (out of the scope of the present study)     -     -       (77) % Scalories from protein (%)     No (out of the scope of the present study, and intrinsically inked to other markers)     -       (76) Calorie intake (g/kg/day)     No (out of the scope of the pre		after awakening	Vee	No
(b) Jamby Colls of Vision (2) (2) (2) (2) (2) (2) (2) (2) (2) (2)		(02) Salivary contisol (ng/dL) at 4 p.m.	Voc	No
(b)       (b)       (b)       (b)         (c)       (b)       (b)       (b)         (c)       (c)       (c)       (c)         (c)       (c)       (c)       (c)         (c)       (c)       (c)       (c)       (c)         (c)       (c)       (c)       (c)       (c)       (c)         (c)       (c)       (c)       (c)       (c)       (c)         (c)       (c)       (c)       (c)       (c)       (c)       (c)         (c)       (		(64) Cortisol awakening response (CAB)	Yes	No
p.m. salivary cortisol (%) CLINICAL PARAMETERS CLINICAL PARAMETERS Sleeping and social (66) Duration of night sleep quality (0-10) (67) Self-reported sleep quality (0-10) (68) Self-reported libido (0-10) (69) Number of hours of activities besides professional training (tr/day) (70) Initial innsonia (Y/N) No (qualitative marker) (71) Terminal imnsonia (Y/N) No (qualitative marker) (72) More than two wake-ups during sleep (Y/N) (73) Work and/or study (Y/N) No (qualitative marker) (74) Libido during resting periods / vacations (0-10) (75) Calorie intake (kcal/kg/day) No (out of the scope of the present study) (77) % calories from carbohydrate (%) No (out of the scope of the present study) (79) % calories from protein (%) No (out of the scope of the present study) (79) % calories from protein (%) No (out of the scope of the present study) (79) % calories from protein (%) No (out of the scope of the present study) (79) % calories from protein (%) No (out of the scope of the present study) (80) Fat intake (g/kg/day) No (out of the scope of the present study) (81) % calories from protein (%) No (out of the scope of the present study) (81) % calories from fat (%) No (out of the scope of the present study) (81) % calories from fat (%) No (out of the scope of the present study) (81) % calories from fat (%) No (out of the scope of the present study) (81) % calories from fat (%) No (out of the scope of the present study) (81) % calories from fat (%) No (out of the scope of the present study) (82) Carbohydrate intake of the scope of the present study and a g/kg/day (Y/N) No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present study) and No (out of the scope of the present st		(65) Difference between 8 a.m. and 4	No (non-validated marker)	-
CLINICAL PARAMETERS       Side provided in the seque (h/night)       Yes       No         Sideping and social characteristics       (66) Duration of night sleep (h/night)       Yes       Yes         (67) Self-reported biolog (0-10)       No (out of the scope of the present study)       No         (68) Self-reported biolog (0-10)       Yes       Yes         (70) Initial immsonia (Y/N)       No (qualitative marker)       -         (71) Terminal immsonia (Y/N)       No (qualitative marker)       -         (72) More than two wake-ups during sleep (Y/N)       No (qualitative marker)       -         (73) Work and/or study (Y/N)       No (qualitative marker)       -         (74) Libido during resting periods / vacations (0-10)       No (qualitative marker)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (76) Carbohydrate intake (g/kg/day)       No (out of the scope of the present study)       -         (77) % calories from carbohydrate (%)       No (out of the scope of the present study)       -         (77) % calories from protein (%)       No (out of the scope of the present study)       -         (77) % calories from fart (%)       No (out of the scope of the present study)       -<		p.m. salivary cortisol (%)		
Seeping and social characteristics       (66) Duration of night sleep (h/night) (67) Self-reported sleep quality (0-10) (68) Self-reported libido (0-10) (69) Number of hours of activities besides professional training (h/day) (70) Initial imnsonia (Y/N)       No (out of the scope of the present study)       No         (71) Terminal imnsonia (Y/N) (72) More than two wake-ups during sleep (Y/N) (73) Work and/or study (Y/N)       No (qualitative marker)       -         (73) Work and/or study (Y/N) (74) Libido during resting periods / vacations (0-10)       No (qualitative marker)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (76) Carbio intake (kcal/kg/day)       No (out of the scope of the present study)       -         (77) % calories from carbohydrate (%)       No (out of the scope of the present study)       -         (77) % calories from carbohydrate (%)       No (out of the scope of the present study)       -         (78) Protein intake (g/kg/day)       No (out of the scope of the present study)       -         (79) % calories from protein (%)       No (out of the scope of the present study)       -         (79) % calories from protein (%)       No (out of the scope of the present study)       -         (79) % calories from from fat (%)       No (out of the scope of the present study)       -         (80) Fat intake (g/kg/day)       No (out of the scope of the present study, and intrinsically linked to other markers)<	CLINICAL PARAMETERS			
characteristics       (67) Self-reported sleep quality (0–10)       No (out of the scope of the present study)       No         (68) Self-reported sleep quality (0–10)       Yes       Yes       No         (69) Number of hours of activities       Yes       No         (70) Initial imnsonia (Y/N)       No (qualitative marker)       -         (71) Terminal imnsonia (Y/N)       No (qualitative marker)       -         (72) More than two wake-ups during       No (qualitative marker)       -         (73) Work and/or study (Y/N)       No (qualitative marker)       -         (74) Libido during resting periods /       No (out of the scope of the present study)       -         (74) Libido during resting periods /       No (out of the scope of the present study)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (76) Carbohydrate intake (g/kg/day)       No (out of the scope of the present study)       -         (77) % calories from carbohydrate (%)       No (out of the scope of the present study, and       -         (77) % calories from protein (%)       No (out of the scope of the present study, and       -         (78) Protein intake (g/kg/day)       No (out of the scope of the present study, and       -         (80) Fat intake (g/kg/day)       No (out of the scope of the present study, and	Sleeping and social	(66) Duration of night sleep (b/night)	Yes	No
(68) Self-reported libido (0-10)       Yes       Yes         (69) Number of hours of activities       Yes       No         (69) Number of hours of activities       Yes       No         (70) Initial imnsonia (Y/N)       No (qualitative marker)       -         (71) Terminal imnsonia (Y/N)       No (qualitative marker)       -         (72) More than two wake-ups during       No (qualitative marker)       -         (73) Work and/or study (Y/N)       No (qualitative marker)       -         (74) Libido during resting periods / vacations (0-10)       No (qualitative marker)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (75) Calorie intake (g/kg/day)       No (out of the scope of the present study)       -         (78) Protein intake (g/kg/day)       No (out of the scope of the present study)       -         (79) % calories from protein (%)       No (out of the scope of the present study)       -         (80) Fat intake (g/kg/day)       No (out of the scope of the present study)       -         (81) % calories from fat (%)       No (out of the scope of the present study)       -         (82) Carbohydrate intake (g/kg/day)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (82) Carbohydrate intake > 3       No	characteristics	(67) Self-reported sleep quality (0–10)	No (out of the scope of the present study)	No
(69) Number of hours of activities besides professional training (r/day)YesNo(70) Initial immsonia (Y/N)No (qualitative marker)-(71) Terminal immsonia (Y/N)No (qualitative marker)-(72) More than two wake-ups during sleep (Y/N)No (qualitative marker)-(73) Work and/or study (Y/N)No (qualitative marker)-(74) Libido during resting periods / vacations (0-10)No (out of the scope of the present study)-(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study, and-(77) % calories from carbohydrate (%)No (out of the scope of the present study, and-(79) Protein intake (g/kg/day)No (out of the scope of the present study, and-(79) % calories from protein (%)No (out of the scope of the present study, and-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and-(81) % calories from fat (%)No (out of the scope of the present study, and-(82) Carbohydrate intake > 3No (out of the scope of the present study and a-(82) Carbohydrate intake > 3No (out of the scope of the present study and a-(83) Daily whey proteinNo (out of the scope of the present study and a-(83) Daily whey proteinNo (out of the scope of the present study and a-(84) Followed a diet plan (Y/N)qualitative marker)No (out of the scope of the present study and a <td></td> <td>(68) Self-reported libido (0–10)</td> <td>Yes</td> <td>Yes</td>		(68) Self-reported libido (0–10)	Yes	Yes
besides professional training (h/day)No (qualitative marker)-(70) Initial imnsonia (Y/N)No (qualitative marker)-(71) Terminal imnsonia (Y/N)No (qualitative marker)-(72) More than two wake-ups during sleep (Y/N)No (qualitative marker)-(73) Work and/or study (Y/N)No (qualitative marker)-(74) Libido during resting periods / vacations (0-10)No (qualitative marker)-(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study)-(77) % calories from carbohydrate (%)No (out of the scope of the present study), and intrinsically linked to other markers)-(78) Protein intake (g/kg/day)No (out of the scope of the present study), and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake (g/kg/day)No (out of the scope of the present study and a g/kg/day (Y/N)-(82) Carbohydrate intake (g/kg/day)No (out of the scope of the present study and a g/kg/day (Y/N)- <td></td> <td>(69) Number of hours of activities</td> <td>Yes</td> <td>No</td>		(69) Number of hours of activities	Yes	No
(70) Initial immsonia (Y/N)No (qualitative marker)-(71) Terminal immsonia (Y/N)No (qualitative marker)-(72) More than two wake-ups during sleep (Y/N)No (qualitative marker)-(73) Work and/or study (Y/N)No (qualitative marker)-(74) Libido during resting periods / vacations (0-10)No (out of the scope of the present study)-(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study)-(77) % calories from carbohydrate (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(78) Protein intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3 Mo (out of the scope of the present study and a intrinsically linked to other markers)-(82) Carbohydrate intake > 3 Mo (out of the scope of the present study and a intrinsically linked to other markers)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a iqualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present		besides professional training (h/day)		
(71) Terminal immsonia (Y/N)No (qualitative marker)-(72) More than two wake-ups during sleep (Y/N)No (qualitative marker)-(73) Work and/or study (Y/N)No (qualitative marker)-(74) Libido during resting periods / vacations (0-10)No (qualitative marker)-(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study)-(77) % calories from carbohydrate (%)No (out of the scope of the present study), and intrinsically linked to other markers)-(78) Protein intake (g/kg/day)No (out of the scope of the present study), and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3 g/kg/day (Y/N)No (out of the scope of the present study and a g/kg/day (Y/N)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(70) Initial imnsonia (Y/N)	No (qualitative marker)	-
(72) More than two wake-ups during sleep (Y/N)No (qualitative marker)-(73) Work and/or study (Y/N)No (qualitative marker)-(74) Libido during resting periods / vacations (0-10)No (qualitative marker)-(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study)-(77) % calories from carbohydrate (%) (77) % calories from protein (%)No (out of the scope of the present study)-(78) Protein intake (g/kg/day)No (out of the scope of the present study)-(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a g/kg/day (Y/N)-(83) Dally whey proteinNo (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(71) Terminal imnsonia (Y/N)	No (qualitative marker)	-
Sileep (Y/N)No (qualitative marker)-(73) Work and/or study (Y/N)No (qualitative marker)-(74) Libido during resting periods / vacations (0–10)No (out of the scope of the present study)-(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(77) % calories from carbohydrate (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(78) Protein intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3 g/kg/day (Y/N)No (out of the scope of the present study and a intrinsically linked to other markers)-(83) Daily whey protein (84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(72) More than two wake-ups during	No (qualitative marker)	-
(74) Work and/of study (Y/N)       No (qualitative marker)       -         (74) Libido during resting periods / vacations (0–10)       No (qualitative marker)       -         (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (76) Carbohydrate intake (g/kg/day)       No (out of the scope of the present study)       -         (77) % calories from carbohydrate (%)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (78) Protein intake (g/kg/day)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (79) % calories from protein (%)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (80) Fat intake (g/kg/day)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (81) % calories from fat (%)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (82) Carbohydrate intake > 3       No (out of the scope of the present study and a intrinsically linked to other markers)       -         (83) Daily whey protein       No (out of the scope of the present study and a consumption (Y/N)       -       -         (84) Followed a diet plan (Y/N)       No (out of the scope of the present study and a qualitative marker)       -		sleep (Y/N)	No (qualitativa postar)	
(14) Ebited during results periods (1-1)       No (qualitative marker)       -         vacations (0-10)       (75) Calorie intake (kcal/kg/day)       No (out of the scope of the present study)       -         (76) Carbohydrate intake (g/kg/day)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (77) % calories from carbohydrate (%)       No (out of the scope of the present study)       -         (78) Protein intake (g/kg/day)       No (out of the scope of the present study)       -         (79) % calories from protein (%)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (80) Fat intake (g/kg/day)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (81) % calories from fat (%)       No (out of the scope of the present study, and intrinsically linked to other markers)       -         (82) Carbohydrate intake > 3       No (out of the scope of the present study and a g/kg/day (Y/N)       -         (83) Daily whey protein       No (out of the scope of the present study and a consumption (Y/N)       -         (84) Followed a diet plan (Y/N)       No (out of the scope of the present study and a qualitative marker)       -		(73) WORK and/or sludy (1/N) (74) Libido during resting periods /	No (qualitative marker)	-
(75) Calorie intake (kcal/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study)-(77) % calories from carbohydrate (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(78) Protein intake (g/kg/day)No (out of the scope of the present study)-(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a g/kg/day (Y/N)-(83) Daily whey proteinNo (out of the scope of the present study and a consumption (Y/N)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		vacations $(0-10)$	No (qualitative marker)	
(73) Galorie intake (kda/kg/day)No (out of the scope of the present study)-(76) Carbohydrate intake (g/kg/day)No (out of the scope of the present study)-(77) % calories from carbohydrate (%)No (out of the scope of the present study)-(78) Protein intake (g/kg/day)No (out of the scope of the present study)-(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a g/kg/day (Y/N)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(75) Caloria intako (koal/kg/dav)	No (out of the scope of the present study)	
(77) % calories from carbohydrate (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(78) Protein intake (g/kg/day)No (out of the scope of the present study)-(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study, and intrinsically linked to other markers)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a g/kg/day (Y/N)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(76) Carbohydrate intake (g/kg/day)	No (out of the scope of the present study)	-
(P) No calcrice from protein (%)No (out of the scope of the present study)-(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a g/kg/day (Y/N)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(77) % calories from carbohydrate (%)	No (out of the scope of the present study, and	-
<ul> <li>(78) Protein intake (g/kg/day)</li> <li>(79) % calories from protein (%)</li> <li>(80) Fat intake (g/kg/day)</li> <li>(80) Fat intake (g/kg/day)</li> <li>(81) % calories from fat (%)</li> <li>(82) Carbohydrate intake &gt; 3</li> <li>(82) Carbohydrate intake &gt; 3</li> <li>(82) Carbohydrate intake &gt; 3</li> <li>(83) Daily whey protein</li> <li>(83) Daily whey protein</li> <li>(84) Followed a diet plan (Y/N)</li> <li>(84) Followed a diet plan (Y/N)</li> <li>(85) Carbohydrate integration (Y/N)</li> <li>(86) Followed a diet plan (Y/N)</li> <li>(87) Ko (out of the scope of the present study and a qualitative marker)</li> <li>(84) Followed a diet plan (Y/N)</li> <li>(85) Carbohydrate integration (Y/N)</li> <li>(86) Followed a diet plan (Y/N)</li> <li>(87) Carbohydrate integration (Y/N)</li> <li>(88) Followed a diet plan (Y/N)</li> <li>(89) Carbohydrate integration (Y/N)</li> <li>(80) Carbohydrate integration (Y/N)</li> <li>(81) Followed a diet plan (Y/N)</li> <li>(82) Carbohydrate integration (Y/N)</li> <li>(83) Carbohydrate integration (Y/N)</li> <li>(84) Followed a diet plan (Y/N)</li> <li>(85) Carbohydrate integration (Y/N)</li> <li>(86) Followed a diet plan (Y/N)</li> <li>(87) Carbohydrate integration (Y/N)</li> <li>(88) Followed a diet plan (Y/N)</li> <li>(89) Carbohydrate integration (Y/N)</li> <li>(80) Carbohydrate integration (Y/N)</li> <li>(81) Followed a diet plan (Y/N)</li> <li>(82) Carbohydrate integration (Y/N)</li> <li>(83) Carbohydrate integration (Y/N)</li> <li>(84) Followed a diet plan (Y/N)</li> <li>(85) Carbohydrate integration (Y/N)</li> <li>(86) Followed a diet plan (Y/N)</li> <li>(87) Carbohydrate (Y/N)</li> <li>(87) Carbohydrate (Y/N)</li> <li>(88) Followed a diet plan (Y/N)</li> <li>(80) Carbohydrate (Y/N)</li> <li>(81) Carbohydrate (Y/N)</li> <li>(82) Carbohydrate (Y/N)</li> <li>(83) Carbohydrate (Y/N)</li> <li>(84) Followed (Y/N)</li> <li>(85) Carbohydrate (Y/N)</li> <li>(85) Carbohydrate (Y/N)</li> <li>(85) Carbohydrate (Y/N)</li> <li>(85) Carbohydrate (Y/N)</li> <li>(86) Carbohydrate (Y</li></ul>		() /	intrinsically linked to other markers)	
(79) % calories from protein (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(80) Fat intake (g/kg/day)No (out of the scope of the present study)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a q/kg/day (Y/N)-(83) Daily whey proteinNo (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(78) Protein intake (g/kg/day)	No (out of the scope of the present study)	-
intrinsically linked to other markers) (80) Fat intake (g/kg/day) No (out of the scope of the present study) - (81) % calories from fat (%) No (out of the scope of the present study, and intrinsically linked to other markers) (82) Carbohydrate intake > 3 No (out of the scope of the present study and a g/kg/day (Y/N) qualitative marker) (83) Daily whey protein No (out of the scope of the present study and a consumption (Y/N) qualitative marker) (84) Followed a diet plan (Y/N) No (out of the scope of the present study and a qualitative marker) (84) Followed a diet plan (Y/N) No (out of the scope of the present study and a qualitative marker)		(79) % calories from protein (%)	No (out of the scope of the present study, and	-
(80) Fat intake (g/kg/day)No (out of the scope of the present study)-(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a qualitative marker)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a qualitative marker)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N) qualitative marker)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-			intrinsically linked to other markers)	
(81) % calories from fat (%)No (out of the scope of the present study, and intrinsically linked to other markers)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a qualitative marker)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a qualitative marker)-		(80) Fat intake (g/kg/day)	No (out of the scope of the present study)	-
(82) Carbohydrate intake > 3No (out of the scope of the present study and a qualitative marker)-(82) Carbohydrate intake > 3No (out of the scope of the present study and a qualitative marker)-(83) Daily whey protein consumption (Y/N)No (out of the scope of the present study and a qualitative marker)-(84) Followed a diet plan (Y/N) qualitative marker)No (out of the scope of the present study and a qualitative marker)-		(81) % calories from fat (%)	No (out of the scope of the present study, and	-
(82) Carbonyorate intake > 3No foul of the scope of the present study and a-g/kg/day (Y/N)qualitative marker)-(83) Daily whey proteinNo (out of the scope of the present study and a-consumption (Y/N)qualitative marker)-(84) Followed a diet plan (Y/N)No (out of the scope of the present study and a-qualitative marker)No (out of the scope of the present study and a-qualitative marker)No (out of the scope of the present study and a-qualitative marker)No (out of the scope of the present study and a-		(20) Carbaby drata int-1	Intrinsically linked to other markers)	
(83) Daily whey protein consumption (Y/N) (84) Followed a diet plan (Y/N) (84) Followed a diet plan (Y/N) (85) Followed a diet plan (Y/N) (86) Followed a diet plan (Y/N) (86) Followed a diet plan (Y/N) (86) Followed a diet plan (Y/N) (87) Followed a diet		$(o_2)$ Carbonydrate Intake > 3	IND (OUT OF THE SCOPE OF THE PRESENT STUDY and a	-
(84) Followed a diet plan (Y/N) (84) Followed a diet plan (Y/N) No (out of the scope of the present study and a - qualitative marker)		yryrudy (1/19) (83) Daily whey protein	Yuaiilalive IIIaikel)	_
(84) Followed a diet plan (Y/N) No (out of the scope of the present study and a - qualitative marker)		consumption (Y/N)	qualitative marker)	
qualitative marker)		(84) Followed a diet plan (Y/N)	No (out of the scope of the present study and a	-
		• • •	qualitative marker)	

(Continued)

Tests	Markers	Initially elected? (Provide independent data, provide additional data (in relation to other parameters evaluated), substantiated/validated)	Significantly different between OTS-affected and healthy athletes? (If "Yes," included in the present analysis)
	(85) Post-workout carbohydrate intake > 0.5 g/kg (Y/N; only applicable for athletes)	No (out of the scope of the present study and a qualitative marker)	-
Psychological patterns	(86) Profile of Mood State (POMS) scale (total score:-32 to +120)	Yes	Yes
	(87) Anger subscale (0–48)	Yes	Yes
	(88) Confusion subscale (0–28)	Yes	Yes
	(89) Depression subscale (0–60)	Yes	Yes
	(90) Vigor subscale (0–32)	Yes	Yes
	(91) Fatigue subscale (0–28)	Yes	Yes
	(92) Tension subscale $(0-36)$	Yes	Yes
	(93) Have you been sick in the last 2 weeks? (Y/N) ?	No (alone does not determine status, and a qualitative marker)	-
	(94) How was your last training session compared to the projected goals? (Extremely easy to extremely hard)	No (alone does not determine status)	-
	(95) How do your muscles feel? (Nothing at all to extremely painful)	No (alone does not determine status)	-
	(96) How friendly do you feel today? (0–6)	No (alone does not determine status)	-
	(97) How worthless do you feel today? (0–6)	No (alone does not determine status)	-
	(98) How miserable do you feel today? (0–6)	No (alone does not determine status)	-
	(99) How helpful do you feel today? (0–6)	No (alone does not determine status)	-
	(100) How bad-tempered do you feel today? (0–6)	No (alone does not determine status)	-
	(101) How unworthy do you feel today? (0–6)	No (alone does not determine status)	-
	(102) How peeved do you feel today? (0–6)	No (alone does not determine status)	-
	(103) How cheerful do you feel today? (0–6)	No (alone does not determine status)	-
	(104) How sad do you feel today? (0–6)	No (alone does not determine status)	-
	(105) How do you fell today? (0-10)	No (alone does not determine status)	-
Body metabolism analysis	(106) Measured-to-predicted basal metabolic rate (BMR, %)	Yes	Yes
	(107) Percentage of fat burning compared to total BMR (%)	Yes	Yes
Body composition	(108) Body fat percentage (%)	Yes	Yes
	(109) Muscle mass percentage (%)	Yes	Yes
	(110) Body water percentage (BW, %)	Yes	Yes
	(111) Extracellular water compared to total BW (%)	Yes	Yes*
	(112) Visceral fat (cm <sup>2</sup> )	Yes	Yes
	(113) Chest-to-waist circumference ratio	Yes	Yes*
	(114) Waist circumference (cm)	No (interpretation may vary, and alone does not determine status or diagnosis)	-
	(115) Chest circumference (cm)	No (interpretation may vary, and alone does not determine status or diagnosis)	-
	(116) Biceps circumference (cm)	No (interpretation may vary, and alone does not determine status or diagnosis)	-
	(117) Hip circumference (cm)	No (interpretation may vary, and alone does not determine status or diagnosis)	-

\*p > 0.05 but < 0.1 between OTS-affected and healthy athletes, but different between athletes (both groups) and sedentary, with possible clinical significance. Bold values: parameters that were selected for the present analysis.

roles in the pathogenesis of OTS. Therefore, in the present study we aimed to uncover the web of multiple interactions that participate in the conditioning processes that occur in athletes, and the underlying mechanisms of the pathophysiology of OTS, derived from an exhaustive yet reasonable joint *posthoc* analysis of the primary findings of the EROS study, using



different and more complex statistical analyses (e.g., multivariate linear regression, logistic regression, and linear correlation analyses) that those employed in the primary arms of the study, which is adequate owing to the large number of data generated by the EROS study (more than 11,000 results among 117 parameters).

Our ultimate objective was to identify independent predictors and linear correlations, and determine causal relationships and inter-influences, among hormonal, immunologic, inflammatory, muscular, psychological, metabolic, and body composition parameters, aiming to uncover behavior patterns and dysfunctional pathways in OTS.

## MATERIALS AND METHODS

## **Subject and Parameter Selection**

The detailed methodology was of the EROS study was previously published (18–22), also available at a depository (https://osf. io/bhpq9/). The present study was approved by the ethical

committee of the Federal University of São Paulo (Approval Number: 1093965).

We recruited participants through social media (Facebook, Instagram, Whatsapp), and were initially evaluated for age, sex, weight and height, clinical characteristics, and if they were suspected for Overtraining Syndrome (OTS), healthy athletes (ATL), or non-physically active (NPAC), and training (if athletes). Inclusion criteria for all participants, criteria for all athletes, and specific criteria for OTS are shown in **Figure 2**. Employing a two-step selection process, we avoided athletes with an insufficient amount of training for the adaptive changes to exercises, non-full sedentary, extremes of age, misdiagnosis of OTS, and presence of confounding hormones, medications, and diseases.

For OTS candidates, we employed the diagnostic flowchart proposed by the latest guideline on OTS (15), the joint guideline of the European College of Sport Science and American College of Sports Medicine, from 2013, which requires the presence of decrease of at least 10% in training intensity, volume, pace, power, strength, or overall performance, decrease of the time-to-fatigue of at least 20%, both verified by a professional coach, increased sense of effort, changes in behavior and decreased energy levels, with or without sleep disturbances, infections or injuries, which persisted for at least 1–2 months, despite the attempts to recover, and which is not caused by conditions that could inherently lead to decrease of performance, including inflammations, infections, and frank hormonal dysfunctions.

#### Design of the Study

## *Summary of the procedures according to each primary arm of the EROS study*

All selected participants signed a written informed consent for participation in the study, approved by the ethics committee of the Federal University of São Paulo, in accordance with the Declaration of Helsinki. Then, participants underwent hormonal responses to stimulation tests, basal biochemical, inflammatory, muscular, immunologic, and hormonal parameters, nocturnal urinary catecholamines (NUC) and its metabolites, analysis of body metabolism and composition, and evaluation of psychological, social, sleep, and eating patterns.

In the EROS-HPA axis arm of the study, we evaluated peripheral and central components of the hypothalamicpituitary-adrenal (HPA) axis (whether primary or peripheral: adrenal, or central: pituitary and hypothalamus), by employing a 250 ug cosyntropin stimulation test (CST), for direct evaluation of cortico-adrenal responses to a synthetic ACTH, an insulin tolerance test (ITT), an exercise-independent stimulation test that provokes a hypoglycemia as the stimulation for the evaluation of the integrity of the HPA axis, and salivary cortisol rhythm (SCR), for the identification of the patterns of the circadian rhythm of the cortisol.

In the EROS-STRESS test we employed the same ITT for the evaluation of the of the growth hormone (GH) and prolactin responses to hypoglycemia, and which we detailed different aspects of the test, including time-to-hypoglycemia, glycemic nadir, severity of adrenergic, and neuroglycopenic symptoms during hypoglycemia, and compared between groups.

In the EROS-BASAL arm, we evaluated basal hormones, immunologic, muscular, classical inflammatory, lipids, and vitamin. And for the EROS-PROFILE, participants underwent several questions regarding specific sleeping, eating, social, and psychological patterns, and underwent analysis of body composition and metabolism.

The full process was performed during a short period, of <10 days, between the recruitment, clinical, and biochemical inclusion and exclusion criteria, the collect of the basal biochemical parameters, all questionnaires, body composition, and metabolism, and functional tests. For all parameters we performed three-group and pairwise comparisons.

#### **Procedures and Tests**

#### Questionnaires

After the selection criteria, athletes (sedentary subjects were not assessed at this moment) underwent an initial specific interview about training patterns, including the type(s) the sport(s) practiced, time since starting the current sport(s), training volume and intensity (evaluated by a professional coach, on a scale from 0 to 10 compared to athletes of the same level of training), duration of training per week (min), number of rest days per week was recorded based on standardized tests, and whether they were supervised by a coach. This first questionnaire aimed to determine the baseline characteristics of the OTS and ATL Groups.

For all athletes affected by OTS, we evaluated whether and the number of days to overcome the underperformance state, changes in sensitivity to heat or to coldness, occurrence of infections, particularly upper respiratory tract infections (URTIs), and injuries, and feelings of monotony and boredom.

All participants (now including the non-physically active group—NPAC) then underwent specific questionnaires regarding sleeping, eating, social, and psychological characteristics.

In terms to eating habits, we employed a 7-day food and nutrition specific record and manually calculated mean daily carbohydrate, fat, protein, and overall caloric intake, aiming to preclude heterogeneity regarding the food analysis. The following specific aspects were evaluated: mean daily (1) carbohydrate, (2) protein, and (3) fat intake (in g/kg), (4) mean daily calorie, total (kcal/day) and per weight (kcal/kg/day), (5) the proportion of carbohydrate, protein and fat intake, (6) whether a diet plan was followed (yes or no), (7) whether there was daily whey protein ingestion, (8) whether post-training carbohydrate intake was > 0.5 g/kg, and (9) whether carbohydrate intake throughout the day was > 4.0 g/kg.

With regards to sleeping patterns, evaluation included the following aspects: (1) self-reported sleep quality (zero to ten; where zero = awful and ten = great), (2) mean duration of sleeping time, (3) whether there was difficulty falling sleep, (4) whether waking up too early and unable to sleep again, and (5) whether waking up more than two times during the night.

For the evaluation of the social aspects, we asked (1) whether participants attended work or study besides the professional training sessions, if so, (2) how many hours per day they attended to the professional activities besides the training periods, and (3)



their self-reported libido, from zero to ten (zero = no sex drive; ten = astonishing sex drive), compared to 1 year before, during the training periods.

With regards to the psychological characteristics, we employed the Profile of Mood States (POMS) questionnaire with the overall and specific mood scales: (1) total score (from -32 to +200; where -32 is the best score and +200 the worst score), (2) anger (from 0 to 48), (3) confusion (from 0 to 28), (4) depression (from 0 to 60), (45 fatigue (from 0 to 28), (6) tension (from 0 to 36), and (7) vigor (from 0 to 32; vigor score is counted as negative for the total POMS score) subscales. In a different

moment of the interview, we also evaluated specific self-reported feelings of (8) general well-being, (9) friendly, (10) worthless, (11) miserable, (12) helpful, (13) bad-tempered, (14) guilty, (15) unworthy, (16) peeved, (17) cheerful, (18) sad, and (19) fatigue [from zero (not fatigued at all) to ten (extremely fatigued)].

The POMS questionnaire and the specific feeling questions were performed by only one author (FAC), in an impartial way, with a constant voice and standardized words of each question in order to prevent "faking good" in ATL and "faking bad" in healthy and OTS-affected athletes, respectively. The RESTQ questionnaire, also used to evaluate athletes, although not validated for non-physically active individual, was not employed, once NPAC were also evaluated as a second group control.

#### **Basal Tests**

Between 36 and 48 h after the last training session (in the case of the groups of athletes), we collected basal fasting levels of the following parameters: CRP; ESR; creatinine; hematocrit, medium corpuscular volume, and numbers of neutrophils, lymphocytes, eosinophils, and platelets (automated assays); CK; ferritin; highdensity lipoprotein-cholesterol and triglycerides (calorimetric enzymatic assays) and low-density lipoprotein-cholesterol (Friedewald equation); **serum** lactate (enzymatic assays); serum total testosterone; estradiol (chemiluminescence assay); serum IGF-1 (chemiluminescence assay); nocturnal 12-h urinary catecholamines and metanephrines (calorimetric enzymatic assays); serum free thyronine (fT3; electrochemiluminescence assay); and serum TSH (electrochemiluminescence assay).

We then calculated the testosterone-to-estradiol, testosterone-to-cortisol, catecholamines-to-metanephrines, neutrophil-to-lymphocyte, and platelet-to-lymphocyte ratios, and compared them between the groups.

#### **Hormonal Functional Tests**

The CST, ITT, and SCR were performed in all participants, in a specific sequence.

#### Cosyntropin stimulation test (CST)

In the first day, we performed a stimulation test with a high doses (250  $\mu$ g) of cosyntropin, a synthetic adrenocorticotropic hormone (ACTH), in order to hormonal responsiveness of the adrenal glands.

For the CST, at 8.00 a.m. (after 30-min resting and 8-h fasting) blood was collected (time 0) from the antecubital vein of the participants for serum cortisol. Immediately, 250  $\mu$ g of cosyntropin was infused intravenously, slowly (during 30 s), and blood was collected at 30 min (time 1) and 60 min (time 2) for the analysis of the cortisol increase, in absolute levels [ $\mu$ g/dL], in response to a synthetic ACTH.

#### Insulin tolerance test (ITT)

Forty-eight hours after the CST, we then performed an ITT, to evaluate the integrity of the HPA, GH, and prolactin axes, once a normal response required absolute unaltered functions in all levels (hypothalamus, pituitary, and adrenals or other glands) of the axes. This is an intrinsic and independent test of the hormonal responsiveness, without interferences from external signaling or systems.

Participants followed the same protocol of at least 8-h fasting, arrival time before 7.30 a.m. and a 30- resting period prior to the beginning of the ITT. Although participants had signed the written consent and were fully aware of the risks of an ITT, before the beginning of the ITT we reminded them of the potential side effects derived from a state of hypoglycemia purposely induced by the test. After agreeing, blood was collected (time 0), and a dose of 0.1 IU/kg of regular insulin was infused in bolus. When hypoglycemia was detected, blood was collected (time 1—during hypoglycemia), 10 mL of 50% glucose solution was given intravenously, and high-glycemic index food was offered *ad libitum* (fat free ice-creams, Diletto, São Paulo, Brazil), blood was finally sampled again, 30 min (time 2) and 60 min (time 3) after the hypoglycemic episode.

The criteria for the detection of the hypoglycemia for the collect of the blood at time 1 was: (1) Asymptomatic hypoglycemia, when capillary glucose was below 30 mg/dL; (2) Moderate-to-intense adrenergic (cold sweating, shakiness, pallor, heart palpitations) and/or neuroglycopenic (mood changes, unrest, sleepiness) symptoms (a score of 5–10, from a zero to ten scale), regardless of the glucose levels; and (3) Capillary glucose below 45 mg/dL associated with any adrenergic or neuroglycopenic symptom.

Serum glucose (mg/dL), cortisol ( $\mu$ g/dL), ACTH (pg/mL), GH ( $\mu$ g/L), and prolactin (ng/mL) were collected at all times. During the ITT, time-to-hypoglycemia (minutes since the insulin infusion), and level of intensity of adrenergic and neuroglycopenic symptoms (zero to ten, self-reported) were also evaluated during the ITT. Absolute increase of cortisol, prolactin, GH, and ACTH, as well as the ACTH/cortisol ratio at all times were calculated. Among these hormones, we adjusted GH for body composition, since GH release is negatively influenced by body fat.

Given the actual risk of ITT-induced severe hypoglycemia (loss of consciousness), three doses of subcutaneous glucagon (GlucaGen HypoKit, 1  $\mu$ g, NovoNordisk), syringes containing 20 mL of 50% glucose solution and an automated external defibrillator (AED) were available.

#### Salivary cortisol rhythm (SCR)

Between 2 and 7 days after the ITT, we collected the SCR, including the collect of the saliva at the awakening moment, at 30 min after awakening, at 4 and at 11 p.m. which were collected by the participants themselves, using laboratory kits provided by the researcher (FAC). Specific recommendations for the self-collect of the samples were provided.

All hormones from the functional tests were analyzed by specific electrochemiluminescence assays using specific commercial kits (Roche), while serum glucose was analyzed by an enzymatic assay of hexokinase.

All biochemical data were determined using standardized commercial assay kits ((18–21), https://osf.io/bhpq9). The interand intra-assay coefficients of variability were lower than 3.5 and 3%, respectively.

#### Body Composition and Metabolism

On a different day from the CST, ITT, or CST, previously scheduled, and after at least 24 h of the last training session (for OTS and ATL), we performed the evaluation of body composition using a gold-standard air-displacement pletimosgraph (Bod Pod, CosMed, USA) for analysis of body fat in terms of weight (kg) and percentage (%), and a validated and standardized electrical bioimpedance scale (InBody770, Biospace, South Korea) for analysis of visceral fat (%), muscle mass (kg), percentage of lean mass (%), body water (liters), percentage of body water (%), and percentage of extracellular water (%). We then measured chest, biceps, and waist circumferences using a standardized and highly accurate pro-body- scanner and (Styku, USA). An indirect calorimetry (Spirostik, Geratherm Respiratory, Germany) was performed to evaluate basal metabolic rate (BMR) (kcal/day), the measured-to-predicted BMR ratio (%), after adjustments for age, weight, height and sex, and fat oxidation in relation to total metabolic rate (%).

#### Selection of the Markers for the Analysis of Associations, Predictions, and Correlations Between Markers

We initially excluded 48 of the 117 markers present in the EROS study, by excluding those that were intrinsically linked to other parameters (seven markers), did not determine diagnoses or status (16 markers), were qualitative indices (nine markers), markers that did not provide additional independent data (two markers), markers that were not the behavioral consequences of exercise (four markers), and invalid and/or unsubstantiated data (nine markers) (**Table 1**). We then selected the 38 from the 69 remaining markers that yielded significant differences between the two groups of athletes: OTS-affected athletes and healthy athletes (34 markers), or that were significantly different between these groups and sedentary controls (p < 0.05) with trends to be significantly different between healthy and OTS-affected athletes (p < 0.1) (four markers).

## **Statistical Analysis**

We used multivariate linear regression to analyze all possible combinations of the 38 parameters that were evaluated in the EROS study (18–21). The intent was to identify: (1) clinical or biochemical markers (including hormonal, metabolic, and body metabolism and composition markers) as independent predictors of other markers and (2) strong linear correlations among the parameters evaluated in the EROS study (18–21). As the identification of triggers and the influence of OTS were not evaluated in the present study, they were excluded from the analyses.

We used multivariate linear regression with a removal criterion of p > 0.01. The standardized residual variables of the last model were examined for normality and homoscedasticity. The cut-off for the presence of multicollinearity was a tolerance index of  $0.40^3$  for the variables in the last model. A *p*-value < 0.05 was considered statistically significant for independent predictors, and p < 0.01 for linear correlations (with >0.40 correlation coefficient), which we considered to unveil moderate-to-strong correlations.

Although r > 0.4 is generally considered to be of moderate association, there is no rule or universally accepted sizes of correlation to be considered as weak, moderate or strong. Since we studied entirely different biological aspects, and each of these aspects is extensively influenced by a large number of different predictors from different natures, it is unlikely to find a single linear correlation > 0.5 (> -0.5), since each parameter tends to be driven by multiple factors. Hence, in this particular case, according to the literature, a correlation > 0.4 is sufficient to be considered as a strong correlation (25–27), or at least moderateto-strong. The *p*-value for the linear correlations was lower and partial correlations were not considered to avoid incidental misinterpretative correlations. Analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA).

Parameters that were independently influenced by OTS, as published in the EROS-DISRUPTORS study (24), were adjusted according to the level of influence of OTS, in order to homogenize the groups of athletes. The biological behaviors that were modified by the presence of OTS include: (1) cortisol 30 min after hypoglycemia, in response to an ITT (26.1% of influence by OTS); (2) cortisol increase during ITT (22.0%); (3) GH 30 min after hypoglycemia, in response to an ITT (23.0%); (4) testosterone-to-estradiol (T:E) ratio (30.7%); (5) neutrophils (13.8%); (6) neutrophil-to-lymphocyte ratio (13.6%) (7) Profile of Mood States (POMS) vigor subscale (83.6%); (8) POMS fatigue subscale (85.7%); (9) POMS tension subscale (42.8%); (10) muscle mass (33.7%); (11) body water (50.5%), and (12) visceral fat (38.2%).

Those parameters that were not modified by the presence of OTS did not require adjustments according to the population (if OTS-affected or if healthy athletes), since these markers behaved independently from OTS.

Correlations that were unlikely to have any biological plausibility were excluded.

Further information on the material, methods, individualized results, and the raw data are provided at a repository (https://osf. io/bhpq9/).

## RESULTS

## **Primary Results**

All sub-groups had similar age, BMI, and training patterns. As per selection criteria, all 34 parameters were significantly different between OTS-affected and healthy athletes. The primary results of these markers are detailed in **Table 2**.

From the primary findings, further statistical analyses were employed, including the analyses for predictions and linear correlations, which are presented in **Table 3** and **Figure 3** [when >0.40 (p < 0.01)], respectively.

## Independent Predictors of Clinical, Metabolic, and Biochemical Biomarkers

None of the hormonal responses to the CST of the adrenal glands or the ITT predicted or was predicted by any of the other clinical or biochemical markers.

Conversely, among the basal hormones, the testosteroneto-estradiol (T:E) ratio, identified in the EROS study as a better predictor of performance and overall status than total testosterone or estradiol alone (21), positively predicted the measured-to-predicted BMR ratio (**Figures 4A,B**), as well as the chest-to-waist circumference ratio. Total testosterone was inversely predicted by fat mass (**Figures 4C,D**), and estradiol inversely predicted anger, both fat mass and anger mood were also influenced by the presence of OTS (24).

Body water content positively predicted fat oxidation (Figures 4E,F) and chest-to-waist circumference was inversely predicted by visceral fat (in addition to the T:E ratio)

#### TABLE 2 | Primary results of the markers selected for the present analysis.

Tests	OTS-affected athletes	Healthy athletes	Significance
BASAL BIOCHEMICAL TESTS			
Total testosterone (ng/dL)	422 (+173 2)	540 3 (+171 4)	p = 0.008
Estradiol (og/ml.)	40.1 (+10.8)	29.8 (+13.9)	$\rho = 0.000$
Total catecholamines ( $\mu \alpha/12 h$ )	257 (+66)	175 (+69)	p = 0.001
Dopamine ( $\mu g/12h$ )	227 (+159)	149 (±60)	p = 0.010
Salivary cortisol (ng/dL) 30 min after awakening	324 (+116)	$500(\pm 168)$	p = 0.005
Lactate (nMol/L)	1 11(0.79  to  2.13)	0.78 (0.47-1.42)	p = 0.003
Neutrophils (mm <sup>3</sup> )	2986 (+761)	3809 (+1431)	p = 0.022
Creatine kinase (CK. U/L)	569 (126 to 3012)	347 (92 to 780)	p = 0.038
Testosterone-to-oestradiol ratio	10.8 (+3.7)	20.8 (+9.9)	p = 0.000
Neutrophil-to-lymphocyte ratio	1 23(+0.34)	$200(\pm 120)$	p = 0.008
Lymphocyte (mm <sup>3</sup> )*	2498 (±760)	2154 (±640)	*(NPAC = $2819\pm810$ ) $p = 0.03$ (overall), $p = 0.018$ (NPAC x ATL) and $p = 0.224$ (NPAC x OTS)
Platelet-to-lymphocyte ratio*	104.1 (±34.2)	119.1 (±43.4)	*(NPAC = 82.4 $\pm$ 19.5) p = 0.017 (overall), p = 0.003 (NPAC x ATL) and p = 0.102 (NPAC x ATL)
HORMONAL FUNCTIONAL TESTS			$0.000 (10 \times 0.000 = 0.102 (10 \times 0.00))$
Basal GH (µ g/l )	0 1 (0 05 to 0 87)	0.26 (0.1 to 1.26)	p = 0.007
Basal prolactin (ng/ml.)	9.2 (5.27 to 19.46)	12 1 (7 19 to 23 0)	p = 0.007 p = 0.048
Cortisol during bypoglycaemia (µg/dL)	12 4 (+3 3)	15.9 (+5.3)	p = 0.022
GH during hypoglycaemia (µg/L)	0.4(0.05  to  4.68)	25(0.08  to  40.94)	$\rho = 0.012$
Prolactin during hypoglycaemia (ng/ml.)	8 95 (4 72 to 47 22)	17 85 (10 0 to 63 39)	$\rho = 0.012$
ACTH 30 min after hypoglycemia (ngr/mL)	30.3 (9.8–93.7)	59.9 (22.1 to 195.7)	p < 0.001
Cortisol 30 min after hypoglycemia (µg/dL)	17.9 (+2.9)	21 7 (+3 1)	$\rho < 0.001$
GH 30 min after hypoglycemia (µg/L)	1.28 (0.03 to 13.95)	12 73 (1 1 to 38 1)	p < 0.001
Prolactin 30 min after hypoglycemia (ng/ml.)	11 35 (4 5 to 25 88)	24.3 (10.5 to 67.45)	p < 0.001
ACTH response to ITT (pg/mL)	9.7 (-14.4 to +64.4)	45.1 (22.1 to 195.7)	p < 0.001
CLINICAL PARAMETERS			
Self-reported libido (0–10)	6.2 (±2.1)	8.3 (±1.7)	$\rho = 0.004$
POMS questionnaire (Total score: -32 to +120)	+54.5 (-14.8 to +89.2)	-9.0 (-23.4 to +17.2)	ρ < 0.001
Anger subscale (0 to 48)	15.0 (4.0 to 21.0)	5.0 (0.2 to 15.0)	$\rho = 0.003$
Confusion subscale (0 to 28)	5.0 (1.6 to 17.1)	2.00 (0.0 to 5.0)	p = 0.001
Depression subscale (0 to 60)	7.5 (0.0 to 21.4)	0 (0.0 to 5.0)	p = 0.008
Vigor subscale (0 to 32)	9.5 (3.6 to 20.1)	26.0 (21.2 to 28.0)	p < 0.001
Fatigue subscale (0 to 28)	20.0 (9.3 to 26.7)	2.0 (0.0 to 4.8)	p < 0.001
Tension subscale (0 to 36)	16.5 (3.6 to 20.1)	6.0 (1.0 to 14.4)	p < 0.001
BODY PARAMETERS			
Measured-to-predicted basal metabolic rate (BMR, %)	102.6 (±8.3)	109.7 (±9.3)	p = 0.012
Percentage of fat burning compared to total BMR (%)	33.5 (±21.0)	58.7 (±18.7)	<i>p</i> < 0.001
Body fat percentage (%)	17.0 (±6.0)	10.8 (±4.2)	p < 0.001
Muscle mass percentage (%)	47.2 (±3.8)	50.5 (±2.3)	$\rho = 0.008$
Body water percentage (BW, %)	59.5 (±3.9)	64.7 (±2.7)	p < 0.001
Visceral fat (cm <sup>2</sup> )	67.5 (±36.5)	35.7 (±20.6)	p = 0.01
Extracellular water compared to total BW (%)*	20.1 (±12.0)	21.8 (±11.8)	*(NPAC = $33.1\pm16.7$ ) $p = 0.022$ (overall), $p = 0.010$ (NPAC = $33.1\pm16.7$ )
Chest-to-waist circumference ratio*	1.276 (±0.068)	1.249 (±0.062)	*(NPAC $\times$ ATL) and $p = 0.083$ (NPAC $\times$ OTS) *(NPAC = 1.157 $\pm$ 0.069) $p = 0.001$ (overall), $p = 0.0005$ (NPAC $\times$ ATL) and $p = 0.002$ (NPAC $\times$ OTS)

\*These parameters were included because although p-value is above 0.05 between OTS-affected and healthy athletes, this is below 0.1, were significantly different between athletes (both groups) and sedentary (p < 0.05), and has potential physiopathological and clinical significance.

BW, Body Weight; POMS, Profile of mood states; BMR, Basal metabolic rate; T/E, Testoterone-to-estradiol ratio; OTS, Overtraining syndrome.

(**Figures 4G,H**), which was also predicted by OTS (24). None of the other psychological parameters, muscle mass, other biochemical parameters, or SCR independently predicted or were predicted by any of the other factors evaluated in this study.

Markers not listed in **Table 3** were not independent predictors of other clinical or biochemical behaviors.

## Linear Correlations

Although none of the hormonal responses to the ITT predicted or was predicted by other parameters, both early and late growth hormone (GH), cortisol, and prolactin responses to the ITT were similar and had strong correlations (**Figures 5A-F**). These hormonal responses were positively correlated with vigor, fat

TABLE 3	Clinical or biochemical parameters	as independent predictors of	f other parameters (mi	ultivariate linear regression analysis).
---------	------------------------------------	------------------------------	------------------------	--

Parameter	<i>p</i> of the influence of the modifiable variables	Level of influence by the modifiable variables*	Parameters with significant correlations (and <i>p</i> -value)	Equation for the estimation of the parameter level in male athletes
Total testosterone (ng/dL)	0.0415	8.4%	1. Fat mass (inverse) ( <i>p</i> = 0.0415)	Testosterone (ng/dL) = $631.77-10.29$ × (fat mass)
POMS anger subscore	0.0006	34.7%	1. Estradiol (inverse) ( $p = 0.008$ ) 2. Presence of OTS (direct) ( $p = 0.003$ )	$\begin{array}{l} \mbox{POMS anger subscore} = 25.43 - 0.24 \\ \times \mbox{ (estradiol)} - 0.24 (T:E \ ratio) + \\ 6.97 (\mbox{if OTS}) \end{array}$
Measured-to-predicted BMR (%)	0.026	10.9%	1. T:E ratio (direct) ( $p = 0.026$ )	BMR ratio (%) = $100.8 + 0.35$ (T:E ratio)
Fat oxidation (% of total BMR)	<0.0001 (together with extra-activities)	58.8%	1. Body water (%) (direct) ( $\rho = 0.001$ )	Fat oxidation = $-66.96 + 2.30x$ (body water) + 0.51 × (T/E ratio)-4.99 × (extra activities)
Chest-to-waist circumference ratio	0.0003	37.8%	1. Visceral fat (inverse) ( $p < 0.0001$ ) 2. T:E ratio (inverse) ( $p = 0.038$ )	$\label{eq:ratio} \begin{split} \text{Ratio} &= 1.3620.012 \times \text{(visceral}\\ \text{fat}\text{)}0.02 \times \text{(T:E ratio)} \end{split}$

\*Adjusted R-Square

POMS, Profile of mood states; BMR, Basal metabolic rate; T/E, Testosterone-to-estradiol ratio; OTS, Overtraining syndrome.

oxidation, the predicted-to-measured BMR ratio, and muscle mass, and they were inversely correlated with fatigue and fat mass. The correlations between late prolactin response to the ITT (30 min after hypoglycemia) and relative BMR (% of predicted), and between late cortisol response to the ITT (30 min after hypoglycemia) and body fat are shown in **Figures 6A,B**, respectively.

Salivary cortisol 30 min after awakening and the T:E ratio were inversely correlated with fatigue, whereas total testosterone was inversely correlated with the Profile of Mood States (POMS) total score (a negative score indicates a better mood), and it was directly correlated with sleep quality. Immunologic parameters were correlated with body composition: body fat was directly correlated with lymphocytes and inversely correlated with the platelet-to-lymphocyte ratio, whereas body water and muscle mass were correlated with these variables in the opposite directions.

Libido and sleep quality were directly correlated with vigor, while sleep quality was directly correlated with libido and inversely correlated with depression, fatigue, and overall mood. Vigor was directly correlated with body water and fat oxidation, and inversely correlated with body fat; conversely, tension was inversely correlated with body water, muscle mass, and fat oxidation, and directly correlated with body fat.

The predicted-to-measured BMR ratio and fat oxidation had a stronger positive correlation with muscle mass and body water, whereas an inverse correlation was found between fat oxidation and body fat. Even though body fat and muscle mass were strongly and inversely correlated (r > -0.95), they were not always correlated in the opposite direction. In addition to fat oxidation, body water was the only parameter directly correlated with muscle mass, and inversely correlated with body fat. Although muscle mass was directly correlated with late GH and cortisol responses to the ITT, extracellular water (i.e., the presence of edema) and body fat were directly correlated with the POMS total score and inversely correlated with vigor.

Though the chest-to-waist circumference ratio was directly correlated with body water, muscle mass, and fat oxidation,

and inversely correlated with body fat, extracellular water was correlated with these variables in the opposite directions (**Figure 6C**). The parameters that are not mentioned in this report failed to show strong correlations (>0.40).

Linear correlations not presented in **Figure 3** were weaker than <0.40 (p > 0.01).

#### DISCUSSION

#### The EROS Study and the Present Analysis

The EROS study elucidated some of the physiological adaptive changes that occur in healthy athletes and how these changes are disrupted in OTS (18–24), as this study addressed the major methodological issues in studies of healthy and OTS-affected athletes, using concurrent comparisons between sex-, age-, and BMI-matched healthy athletes and non-athletes, and simultaneous comparisons of a broad range of aspects within the same participants. The prior results for the two groups analyzed here (healthy and OTS-affected athletes) showed multiple clinical, metabolic, and biochemical conditioning processes in the healthy athletes and a loss of 59.1% of these conditioning processes in the OTS-affected athletes (23), which was referred to as "a mix of paradoxical deconditioning processes."

The concomitant analysis of different biochemical, clinical, and metabolic aspects in the EROS study allowed us to explore the previously uninvestigated interactions, correlations, predictions, and synergistic actions between these parameters, using multivariate regression and other statistical techniques. Therefore, the EROS-CORRELATIONS study analyzed two major sorts of interactions among basal and stimulated hormonal, metabolic, immune, and muscular biomarkers, body composition and metabolism, and psychological patterns: independent predictors and linear correlations, as well as their mechanisms and outcomes.

Noteworthy, some markers previously hypothesized to be potential biomarkers for OTS yielded similar results between OTS and healthy athletes, including the testosterone-to-cortisol ratio (21) and the insulin growth factor-1 (IGF-1) (21). These markers also failed to demonstrate any sort of relationship with other markers, as shown in the raw statistical analysis (https://osf. io/bhpq9).

## **Biochemical Responses as Predictors of Other Biochemical and Clinical Behaviors**

Although fat mass is considered an independent suppressor of the GH response (28), this was not confirmed by our results, in that the body fat of male athletes was not important for the GH response. Although body fat did not have a negative effect on GH release, it reduced testosterone levels; however, the reduction was not due to increased aromatase activity, as the T:E ratio was not reduced by body fat or affected by any of the other markers. Conversely, the T:E ratio positively predicted the measured-topredicted BMR ratio while neither testosterone nor estradiol had the same effect; the T:E ratio also predicted the chest-to-waist circumference ratio the measure of the torso's "V-shape." Our findings underscore the importance of evaluating the ratios of different hormones for the prediction of metabolic outcomes. Although an increase in estradiol without a concurrent analysis of testosterone does not necessarily suggest either a beneficial or a harmful outcome, in this study, testosterone level did not predict any of the parameters, such as body metabolism or composition, without the simultaneous analysis of estradiol. These findings are consistent with studies suggesting a simultaneous increase in testosterone and estradiol has synergistic positive effects, which include metabolic parameters (29-33). Conversely, fat mass reduced testosterone levels, which can be justified by exposure of testosterone to a more intense aromatase enzyme under higher body fat (31, 32).

Although estradiol alone did not predict body metabolism or composition parameters, it independently predicted lower anger. Although estradiol receptors are widely distributed in the brain (29, 33, 34), their effects on mood in males are still unclear. Body water content was the only predictor of fat oxidation, which supports the premise that good hydration status, particularly within the cells, is a key requirement for proper fat oxidation, as water is part of this pathway (35–37), while dehydration slightly impaired fat burning.

## **Linear Correlations**

Strong inter-correlations were found among GH, prolactin, and cortisol for early and late responses to stimulation tests. Therefore, it was impossible to distinguish levels of responsiveness among the corticotropic, somatotropic, and lactotropic axes, as these hormones responded simultaneously and equally, which indicates a common, ubiquitous, and enhanced hypothalamic responsiveness in athletes, compared to sedentary controls. Although ACTH was not strictly correlated with the other hormones, its short half-life precluded drawing conclusions about its correlation with other hormones.

Late hormonal responses (30 min after hypoglycemia) were directly correlated with energy levels (higher vigor and lower fatigue levels), indicating a possible role for sustained hormonal release in response to stress in the prevention of burnout in chronically stressful situations. They were also correlated with increased muscle mass, lower body fat, and better hydration, without a distinction between the specific effects of each hormonal response (cortisol, GH, and prolactin). Acute cortisol and GH release promote fat oxidation and lipolysis, but chronic hypercortisolism may lead to the accumulation of visceral and central fat, even when it is mild.

Overall, the hormonal conditioning process that was found to occur in athletes, and identified by enhanced GH, prolactin and cortisol responses to exercise-independent stimulation tests, when compared to sex-, age-, and BMI-matched healthy sedentary controls, and adjusted for body composition, may be one of the underlying reasons for decreased extracellular water, decreased anger, fatigue, depression, confusion mood states, and indirect account for reduced fat, increased muscle, and better hydration (38). Indeed, under OTS, in which the optimization of the hormonal responses is lost (24), the concurrent benefits in response to intense exercise are also lost.

The inverse correlation between salivary cortisol 30 min after awakening and fatigue supported this parameter and the cortisol awakening response as markers of fatigue, as previously demonstrated by different studies (39-42). Indeed, cortisol awakening response (CAR), an indirect marker of cortisol 30 min after awakening, has been extensively used as a marker of fatigue (43-46). Nonetheless, they were not independent predictors of fatigue when analyzed using multivariate regression. Therefore, a lower increase in cortisol level between awakening and 30 min after awakening is unlikely to be the primary cause of fatigue, but rather a possible consequence of poor sleep quality leading to an impaired cortisol awakening response (47), with a blunted cortisol increase 30 min after awakening and a concurrent decrease in energy level (48-50), as well as other disruptions of the HPA axis (50). Thus, conclusions regarding adrenal function using these tools are inappropriate (51).

Testosterone level was directly correlated with sleep quality. Although this does not indicate a causal relationship, it supports the role of sleep quality in testosterone production because its' physiological peak also occurs in the early morning hours, which is affected by sleep quality (52–54).

The T:E ratio was also inversely correlated with fatigue, which implies that the ratio was a better predictor of energy level than either testosterone or estradiol alone. While estradiol alone was not linked to fatigue, its pathological increase, from an exacerbation of aromatase activity and consequent reduction of testosterone, may have increased fatigue, in accordance with the literature (32).

In the EROS study, although sleep duration did not have a role in psychological function, unlike previous studies, that strongly correlated sleep duration with mood states (49, 55, 56). Sleep quality was strongly correlated with better psychological outcomes, including lower depression and fatigue, and higher vigor, indicating that sleep quality led to a global improvement in mood, similarly to what has been unanimously observed (49, 55, 57–59). We speculate that sleep duration was not demonstrated to a major factor of mood states or any other characteristic in athletes because in higher quality sleep duration tends to play a less important role (60, 61).

Other moderate-to-strong linear correlations were identified. Body water was inversely correlated with lymphocyte and





**FIGURE 4** | Biological predictors of other clinical, metabolic and biochemical parameters. (**A**,**B**) Testosterone-to-estradiol (T:E) ratio as a predictor of basal metabolic ratio (BMR) (relative to the predicted BMR, in %). Estimated equation: BMR ratio (%) = 100.8 + 0.35(T:E ratio)–r = 0.33. (**C**,**D**) Body fat (%) as a predictor of total testosterone (ng/dL) Estimated equation: Testosterone (ng/dL) =  $631.77-10.29 \times$  (fat mass-%)–r = 0.29. (**E**,**F**) Level of hydration (body water, in % of body weight) as a predictor of fat oxidation (% of total BMR) Estimated equation: Fat oxidation =  $-66.96 + 2.30 \times$  (body water) +  $0.51 \times$  (T/E ratio)– $4.99 \times$  (extra activities)–r = 0.77. (**G**,**H**) Visceral fat (cm<sup>2</sup>) as a predictor of chest-to-waist circumference ratio. Estimated equation: Ratio =  $1.362-0.012 \times$  (visceral fat)– $0.02 \times$  (T:E ratio)–r = 0.62. (**A**,**C**,**E**,**G**) Estimated curve for all athletes, adjusted for OTS, when needed. (**B**,**D**,**F**,**H**) Results for athletes of OTS and healthy groups. Each point represents the result of one athlete.

directly correlated with platelet-to-lymphocyte ratio. However, little data has been identified in the literature, specifically for these correlations (62–69), since immune function and hydration has been more assessed in athletes, in response

to exercises (67–69). Specific absolute and lymphocytes subpopulation counting have been assessed in athletes and in patients at high cardiovascular risk, with indirect but inconsistent correlations between lymphocytes and hydration



status (70–75). Platelet-to-lymphocyte ratio has been proposed as an inflammatory marker of cardiovascular risk, acute pancreatitis and sarcopenia (76–80), with some speculations that higher ratio could indicate better hydration status, similarly to the direct linear correlation that we found. This occurs perhaps due to a direct correlation between platelet count and total body water (65, 66, 81), although this associations remain controversial (64–68).

## Associations Between Improved Mood States and Body Composition and Metabolism

Vigor was directly correlated with better hydration, better fat oxidation, and less body fat, whereas libido was exclusively correlated with vigor, indicating improved overall body metabolism and composition, hydration, and fat oxidation. Since vigor has also been correlated with enhanced hormonal responses to stimulations and better sleep quality (24) in the present study, both of which have also been correlated with improved body metabolism and composition patterns, we hypothesize that vigor is an additional consequence of hormonal response and sleep quality, similarly to body composition and metabolism, and has no direct correlations of causal relationship with these parameters.

Conversely, while other moods were not significantly correlated with body metabolism or composition, tension had correlations in the opposite direction than those found for vigor. Oppositely to vigor, which unlikely leads to changes in hormonal responses, tension is likely the mood mostly correlated with disrupted hormonal responses (50). Once in our study tension was the mood state most strictly predicted by sleep quality, and that Impaired sleep independently leads to impaired muscle recovery (62), this may justify the correlations between vigor (positive) and tension (negative) and body muscle identified by the EROS study.

Also, although oxidative stress leads to muscle hypertrophy, chronic stress mediated by the HPA axis, leads to the opposite direction (82-85). Indeed, alterationsof the HPA axis disrupt the metabolism of the muscle tissue, toward a negative balance between protein generation and degradation, eventually leading to muscle mass loss (86-89). Conversely, impaired HPA axis also leads to concurrent independent body fat gain (84), as multiple mechanisms mediated by the HPA axis induce increase of fat cell size and induce a pro-inflammatory status irrespective of caloric balance, proportion of macronutrient intake, and sleeping patterns, since a post-receptor modification from cortisone to cortisol by enhanced activity of 11betahydroxysteroid dehydrogenase type 1(11beta-HSD1) (90, 91). In addition, disruption of the muscle metabolism, herein induced by altered cortisol regulation, has also demonstrated to have direct effects on the metabolism and accumulation of fat (92). Since the HPA axis is chronically and more severely enhanced by high tension levels, more than any other mood state, it would be expected, from this perspective, to find negative correlations between tension levels and body composition. Indeed, higher tension, which have been correlated with impaired hydration and fat oxidation, muscle catabolism, and increased body fat, are possibly due to the harmful metabolic effects of the chronic stimulation of the HPA axis (82-85), although direct effects of tension, depression, and anger on increased body fat has been observed (86).



and extracellular water (% of body water) (R = 0.72).

In additional, overall mood states can hypothetically be indirect signals of hydration status, although direct relationships are unlikely.

# Hydration as a Key Characteristic for Athletes

Level of hydration is a key characteristic for the overall health status in humans, since water is a major participant of multiple reactions of metabolism and thermoregulation (37). Hydration, measured by the % of body water in relation to total body weight, was associated with multiple parameters (20, 22, 34), including both characteristics of body metabolism(the predicted-to-measured BMR ratio and fat oxidation), which is reasonable since water boosts fat metabolism (35, 36, 93, 94, 96) and overall metabolic rate (35, 94, 96–99), being considered as a potential thermogenic (35, 36, 93, 94, 96–98).

The need for a minimum amount of available water content for fat oxidation in catabolic states is conceivable in the context of a direct correlation between hydration and fat oxidation (35, 96). Conversely, the amount of body fat was inversely correlated with fat oxidation, which is expected, once more body fat may be a consequence of less fat utilization as source of energy, even under glycogen- and glucosedepleted circumstances, as observed by some studies (100, 101). Despite the previous reports on the correlation between body fat and fat oxidation, it is still unclear whether a larger fat mass resulted from reduced fat oxidation, or if a greater fat mass impaired fat oxidation through a non-classical inflammatory response that is enhanced in adipocytes when these are enlarged. Finally, since dehydration probably leads to lower fat oxidation, body water was expectedly found to be inversely correlated with body fat and the chest-to-waist circumference ratio.

Similar to the correlation between fat oxidation and body water, the measured-to-predicted BMR ratio was positively correlated with hydration status and muscle mass, which reinforces the extensive descriptions on the literature that body water content, hydration status, and muscle mass are the major components of the metabolic rate (94, 96–99, 102–104). Moreover, hydration has been correlated with vigor levels and other mood states at lesser extent, which is supported by the literature (105).

In regards with the location of the water—whether intraor extracellular—extracellular water accounts for  $\sim$ 40% of total body water (106), which was similar to that observed in the healthy sedentary of the EROS study. However, in healthy athletes extracellular water was shown to be reduced, possibly as a mechanism of facilitation for the optimization of intracellular metabolic pathways. Among which most reactions require water to occur. In the EROS study, in the groups of athletes  $\sim$ 80% of the water was located intracellularly, which can be considered as an improvement of the water balance for metabolic purposes (107). Conversely, fat mass is inversely correlated with relative and absolute intracellular water, and consequently lower body water. Some authors speculate that this is possibly due to the fact that enlarged fat cells tend to become more hydrophobic and to contain less water. However, this is still a hypothesis to be further demonstrated.

We observed an inverse correlation between hydration status and extracellular water, i.e., better hydration was correlated with less edema, indicating that the amount of water consumed may redirect water toward inside cells (the preferred space), rather than interstitially (third space; extracellular water). However, external factors such as disturbed hormonal secretion, excessive sodium intake, and hypercaloric diets may lead to excessive extracellular water, which becomes the primary cause of dehydration: resulted from shifts in water compartment redistribution (106, 108). Indeed, dehydration may not only be a result from redistribution of water, but overall low water content can also induce further dehydration by its accumulation in the extracellular water, as a mechanism of protection against further water wasting, secondarily to vasopressin (ADH) and reninangiotensin-aldosterone-system (RAAS) metabolism (109). In addition, interactions between water content, the RAAS, the HPA axis, the direct aldosterone actions and their relationship with chronic stress have been reported (105, 109).

In the EROS study, the major influences that drove the water destination were the metabolic environment, sleep quality (worse sleep leads to worse hydration and increased edema), the amount of muscle mass, eating patterns, and mood. Muscle mass was positively correlated with body water and it may have indirectly prevented edema, while body fat may have had the opposite effect, similarly to the observed in the literature (86, 98).

## **Implications of the Findings**

The use of additional statistical techniques in this study facilitated the identification of independent predictors of linear correlations among clinical, metabolic, and biochemical parameters and other parameters, which has improved our understanding of hormonal and metabolic behaviors, and their multiple interactions and influences in athletes. They also yielded information to speculate on new potential markers and new understandings of current markers.

The summary of the findings and their possible implications are presented in **Table 3**. Hydration status, and, to a lesser extent, muscle mass, were the two major determinants of metabolic rate and fat oxidation (35, 93–99, 102–104). These results support the importance of adequate water intake and maintaining and building lean muscle for adequate metabolism and fat oxidation. The body fat effect on GH release was attenuated in athletes, while its effect on testosterone was maintained, suggesting that athletes with excessive body fat might not benefit from some of effects of exercise, which is a reason for sports professionals to have a good body shape.

Since the hormonal responses to an ITT were strictly correlated, i.e., the level of increase of GH, cortisol, ACTH, and prolactin was similar within each athlete (**Figure 5**), the level of hypothalamic responsiveness to stimulation seemed to be diffuse, rather than specific for certain axes. Energy levels were strongly correlated with hormonal status, including a prolonged optimization of hormonal responses and a better cortisol response to awakening, although a causal relationship was undefined. In addition to energy levels, better hormonal responses were correlated with better body composition, of which the causal relationship remains uncertain.

Sleep quality seemed to be the most important factor in mood, rather than any other factor, such as hormonal levels or eating patterns, which has been demonstrated to play an essential role on overall cognitive and psychological functions (REF), in accordance with our findings. The level of hydration was inversely correlated with edema and better hydration was linked to less edema, depending on the location of the water in the body, regulated by external factors rather than the amount of water intake.

## Testosterone, Estradiol, and Testosterone-To-Estradiol (T:E) Ratio

Testosterone, estradiol, and their ratio (T:E ratio) had different roles and influences. While testosterone was inversely related to body fat, positively linked to sleep quality, and indirectly linked to improved psychological outcomes, alone, it did not predict any of the parameters. Conversely, estradiol unexpectedly predicted anger, because of its actions on the male brains of the athletes. The T:E ratio had the most important roles in body metabolism and composition, and was linked to energy level. Hence, the balance between testosterone and estradiol might be more important than either testosterone or estradiol alone. This is extensively supported by the literature, since the T:E ratio predicts multiple outcomes, including cardiovascular changes (29, 30), while many of the neuroprotective and psychological effects of estradiol in males are mediated by testosterone (32-34), which requires a balance between these hormones to obtain the health benefits. The unaltered balance is more precisely assessed by the T:E ratio, rather than each hormone alone.

The T:E ratio is a significant ratio that has a promising role in the evaluation of athletes. It was found to be a better predictor of metabolic and psychological parameters than either testosterone or estradiol alone, supporting the hypothesis that it is a potential novel parameter. We based this hypothesis on a new understanding of the role of estradiol in males, and identified two types of estradiol increase: (1) a physiological increase, secondary to an increase in testosterone, when high testosterone levels are maintained and (2) a pathological increase, caused by an aberrant exacerbation of aromatase activity, leading to a decrease in testosterone. We found the most appropriate way to differentiate these situations objectively was to examine the T:E ratio. This ratio indicates whether an increase in estradiol is followed by an increase in testosterone; it should remain unaffected in the case of a physiological increase. These data were supported by a recent study showing that increased estradiol benefitted males in terms of increasing their libido, muscle mass, and bone mass, and reducing their fat mass, but only when accompanied by increased testosterone levels (26-28), which occurs when increased estradiol is actually desirable and the T:E ratio is unaffected (29). Conversely, the estradiol increase that we identified as a marker of OTS was due to a pathological conversion from testosterone, indicated by a substantial decrease in the T:E ratio, which was most likely a response to an anti-anabolic environment. For practical purposes, the T:E ratio should be above 13.7:1 (21).

#### Summary of the Findings

The EROS-CORRELATIONS study demonstrated that testosterone was predicted by fat mass, estradiol predicted anger, and the T:E ratio predicted the measured-to-predicted BMR ratio and chest-to-waist circumference, while hydration status predicted fat oxidation. Early and late somatotropic, corticotropic, and lactotropic responses were strong and strongly correlated, showing a diffuse hypothalamic rather than axisspecific response to stimulation. Late hormonal responses to stimulations, increased cortisol after awakening, and the T:E ratio was correlated with energy level. Sleep quality was the major factor correlated with most of the study's psychological measures, while fat oxidation, hydration, muscle mass, and body fat were highly inter-correlated, and edema was inversely correlated with hydration and muscle mass, and directly correlated with fat mass. The most remarkable findings are described in Table 4.

## LIMITATIONS

The findings of the present study are valid only for male athletes that practice both endurance and strength sports, as basal hormone levels and responses to stimulations are highly sexspecific and may be sport-specific. Hence, different arms of the EROS study focused on purely strength, purely endurance, purely explosive, purely stop-and-go, and mixed sports, conducted with male and female participants, should provide data that are more specific. Given the unexpected findings regarding several hormones and other biochemical markers, we suggest additional parameters for further studies, including luteinizing hormone, follicle-stimulating hormone, sex hormone-binding globulin the tumor necrosis factor-alpha, interleukin-1 beta, lactate dehydrogenase (LDH), free thyroxin-4, and cortisol binding globulin. Longer stimulation tests, including thyrotrophic and gonadotrophic responses (given the unexpected response of the lactotropic axis), and an examination of the associations between exercise-dependent and exercise-independent tests should also be examined. Also, the estradiol levels in males may lose absolute precise using chemoiluminescence, compared to liquid chromatography mass spectrometry/tandem mass (LC/MS-MS/MS). However, the relative precision is highly accurate, which allows the in-between (pairwise) group comparisons as fully satisfactory (110-115).

## FINAL DISCUSSION

We found multiple correlations and predictions between clinical, hormonal, biochemical markers, that occurred as a web of influences, as multiple and multi-directional chain-reactions, that allowed us speculate on several new mechanisms to occur in response to sports. The identification of a complex web of interactions among many different aspects allowed us to hypothesize that sports performance results from a combination of hormonal, energy, and water availability, and psychological and muscular status The predictions, correlations, and interactions revealed in the TABLE 4 | Most remarkable findings of the EROS-CORRELATIONS study.

STREPHONE_ESTRADUC_USE F LEND:       I Sensoral Day (or IP)       I. Bestoration (or IP)         Stratubility       I Destropaid Day (or IP)       I. Bestoration (or IP)       I. Bestoration (or IP)         Stratubility       I Destropaid Day (or IP)       I. Bestoration (or IP)       I. Bestoration (or IP)         Stratubility       I Destropaid Day (or IP)       I. Bestoration (or IP)       I. Bestoration (or IP)         ID: Incrumed of thems: two waits circum freques reads       I. Incrumed of thems: two waits circum freques reads       I. Incrumed of thems: two waits circum freques reads         ID: Incrumed of thems: two waits circum freques reads       I. Destropaid Day (or IP)       I. Incrumed of thems: two waits circum freques reads         ID: Incrumed of thems: two waits circum freques reads       I. Incrumed of thems: two waits circum freques reads       I. Incrumed of thems: two waits circum freques reads         ID: Incrumed of thems: two waits circum freques reads       I. Incrumed thems: two waits circum freques reads       I. Incrumed thems: two waits circum freques reads         ID: Incrumed thems: two waits circum freques reads       I. Incrumed thems: two waits circum freques reads       I. Incrumed thems: two waits circum freques reads         ID: Incrumed thems: two waits circum freques reads       I. Incrumed thems: two waits circum freques reads       I. Incrumed thems: two waits circum freques reads         ID: Incrumed thems: two waits circum freques reads       I. Incrumed thems: two wai	Parameter	Markers	Potential implication(s)
Total sector       (1) Decrements loady fair (P)       1. Tendsatterine is lutined by toody fait.         Entraidi       (1) Lower ange levels (P)       1. Entraide lactors in the main brain improve ange levels.         Test observation 1000       (1) Events and massing levels (P)       1. Entraide lactors in the main brain improve ange levels.         Test observation 1000       (1) Events and massing levels (P)       1. Entraide lactors in the main brain improve ange levels.         OKMONAL FUNCTIONAL TEST       (1) Poralise (intractor intains servation 2000)       1. Hypothalismic responsiveness to stimulators does not discriminate between Offerent and composition.         OKMONAL FUNCTIONAL TEST       (2) Poralise (intractor intains servations C(2), exploring levels (P)       1. Hypothalismic responsiveness to stimulators does not discriminate between Offerent and composition.         (2) Poralise (intractor intains servations C(2), exploring levels (P)       1. Hypothalismic responsiveness to stimulators does not discriminate between Offerent and exploring levels.       2. Attracid passivel (P)         (3) Lower body fait (P)       (2) Poralise (intractor intains servations C(2), exploring levels (P)       1. Servation (P)       2. Attracid level intoid (P)         (1) Hyper total oxidiant (P)       (2) Lower discrime (P)       1. Servation (P)       2. Attracid level intoid (P)         (2) Lower discrime (P)       (2) Lower discrime (P)       1. Servation (P)       2. Attracid level intoid (P)         (1) Hyper total	TESTOSTERONE, ESTRADIOL A	ND T:E RATIO	
(2)       Exter store (see quality may been teststorem production the matching in the production of the market in integrover anger levels         1)       Increased check-to-wait dicturbiemen rate (P)       1. The rate between teststoreme and establish and integring register (see the check of the store (see the store) (see the s	Total testosterone	(1) Decreased body fat (P)	1. Testosterone is blunted by body fat
Estradol (1) Lower ange fereis (P) Estradoron-to-estradol inter (1) Increased request-to-predicted basis metabolic rate (P) (2) Increased request-to-predicted basis metabolic rate (P) (3) Lower faigle levels (C) HORMONAL FUNCTIONAL TESTS CPL policiti, and contrast (2) Positive (direct) inter-correlations between GH, (3) Lower faigle levels (C) HORMONAL FUNCTIONAL TESTS CPL policiti, and contrast (3) Lower faigle levels (C) CPL policity (direct) inter-correlations between GH, (4) Higher (to collastion (C) (5) Extern faigle levels (C) COLL AND PSYCHOLOGICAL ASPECTS Social AND PSYCHOLOGICAL ASPECTS Social Lower faigle levels (C) COLL Lower faigle leve		(2) Better sleep quality (C)	2. Better sleep quality may boost testosterone production
Testesterone to estrated rates (1) Increased measured to predicted base metabolic rate) (2) Increased measured to predicted base (3) Increase stage dresserved to predicted base (4) Increase stage dresserved to predicted base (4) Increase stage dresserved to predicted base (5) Increase stage dresserved to predicted base (6) Increase stage dresserved to predicted base (7) Increase dresserved (7) (7) Increase dresserved (	Estradiol	(1) Lower anger levels (P)	1. Estradiol actions in the male brain improve anger levels
(a) Lower today is the correction between GH.       1. Paperton is an indication and contractions between GH.       1. Apportance is set indications does not discriminate between GH end to a set indications does not discriminate protects in and contraction between GH end to a set indications does not discriminate between GH end to a set indications does not discriminate between GH end to a set indications does not discriminate between GH end to a set indications does not discriminate between GH end to a set indication (C)       1. Apportance is an indications does not discriminate between GH end to a set indication (C)       1. Apportance is an indications does not discriminate between GH end to a set indication (C)       1. Apportance is an indications does not discriminate between GH end to a set indication (C)       1. Beep quality may be more energy and to batter body composition is an indirect marker of less body fat, better fat oxidation, and bower edena.         Social LAND PSYCHOLOGICL LESSEE         Social Land Psychological status of the atheles         Social Land Psychological status of the atheles         Social Land Psychological status of the atheles         Social Land Lesse (S) </td <td>lestosterone-to-estradiol ratio</td> <td><ol> <li>Increased measured-to-predicted basal metabolic rate (P)</li> <li>Increased chest-to-waist circumference ratio (P)</li> </ol></td> <td><ol> <li>The ratio between testosterone and estradiol is more important than testosterone or estradiol alone for body metabolism and composition</li> </ol></td>	lestosterone-to-estradiol ratio	<ol> <li>Increased measured-to-predicted basal metabolic rate (P)</li> <li>Increased chest-to-waist circumference ratio (P)</li> </ol>	<ol> <li>The ratio between testosterone and estradiol is more important than testosterone or estradiol alone for body metabolism and composition</li> </ol>
HORMONAL FUNCTIONAL F		(3) Lower fatigue levels (C)	
GH, practation, and cortisal       (1) Possible (direct) inter-correlations between GH, protectin, and the responses to direct marker or less body can be the thermore responses to direct marker or less body can be there have the advisor of the sector body to the advisor of the sector body can be the sector of the advisor of a a prosche advisor of the adv	HORMONAL FUNCTIONAL TEST	S	
responses to an insum responses response response response response response response response r	GH, prolactin, and cortisol	(1) Positive (direct) inter-correlations between GH,	1. Hypothalamic responsiveness to stimulations does not discriminate
Sincer body fat (C)         Hipber fat oxidation (C)         Sincer ystroation (C)         OCCALL AND PSYCHOLOGICAL ASPECTS         Sincer ystroation (C)         Sincer ystroation (C)         (1) Improved overal mode states (C)         (2) Lower depression levels (C)         (3) Lower depression levels (C)         (4) Hipfer fat oxidation (C)         (5) Lower depression levels (C)         (1) Unower body fat (C)         (2) Hipfer fat oxidation (C)         (3) Batter hydration (C)         (3) Batter hydration (C)         (3) Hipfer fat oxidation (C)         (3) Unower body fat (C)         (4) Hipfer fat oxidation (C)         (4) Lower muscle mass (C)         (5) Depression levels (C)         (4) Hipfer fat oxidation (C)         (3) Unower hydration (C)         (4) Lower muscle mass (C)         (5) Hipfer muscle mass (C)         (6) Hipfer muscle mass (C)         (6) Hipfer muscle mass (C)         (6) Lower body fat (C)         (7) Lower fat oxidation (C)         (6) Lower body fat (C)         (7) Batter hydration (C)         (8) Lower body fat (C)         (9) Hipfer fat oxidation (C)         (9) Lower body fat (C)         (9) Hipfer muscl	tolerance test	<ul> <li>(2) Positive (direct) inter-correlations between GH, prolactin, and cortisol in late responses (C)</li> </ul>	<ol> <li>Although causality is not confirmed, better hormonal responses are at least linked to more energy and to better body composition</li> </ol>
Fight rest booked mass (C)       (C)         (F) Hoyder muscle mass (C)       (C)         (F) Lower fatigue levels (C)       (C)         (F) Lower depression levels (C)       (C)         (F) Hoper extraoellular water (C)       (F) Hoper extraoellular water (C)         (F) Hoper extraoellular water (C)       (F) Hoper extraoellular water (C)         (F) Hoper extraoellular water (C)       (F) Hoper extraoellular water (C)         (F) Hoper muscle mass (C)       (F) Hoper muscle mass (C)         (F) Hoper extraoel (C)       (F) Hoper extraoel (C)         (F) Lower body fat (C)       (F) Hoper muscle mass (C)         (F) Lower body fat (C)       (F) Hoper muscle mass (C)         (F) Lower body fat (C)       (F) Hoper muscle mass (C)         <		(3) Lower body fat (C)	
Simpler instance (c)       Better hydration (C)         (c)       Better hydration (C)         SOCAL AND PSYCHOLOIGUL ASPECTS         Step quality       (1) Improved overal mood states (C)         Siege quality       (1) Improved overal mood states (C)         (2) Lower depression levels (C)         (3) Higher vigor levels (C)         (4) Higher vigor levels (C)         (2) Higher tato addation (C)         (3) Better hydration (C)         (3) Higher vigor levels (C)         (4) Higher vigor levels (C)         (5) Higher tato addation (C)         (3) Korse hydration (C)         (4) Higher vigor levels (C)         (5) Lower level tato addation (C)         (5) Lower level tato addation (C)         (6) Lower muscle mass (C)         BODY METABOLISM AN COMPOSITION         Measured-to-predicted basa         (1) Higher tato addation (C)         (3) Higher muscle mass (C)         Botter hydration (C)         (3) Lower level tatos         (3) Higher muscle mass (C)         Fat addation         (1) Higher tatostatenne-to-estration ratio (P)         (3) Higher muscle mass (C)         (3) Lower level has (C)         (3) Higher muscle mass (C)         (3) Lower level has (C)		(4) Higher fat oxidation (C)	
Constant System (C)         SOCIAL AND PSYCHOLOGICAL ASPECTS         Social AND Psychological status of this system (C)         (2) Lower depresion levels (C)         (3) Loss fatgue levels (C)         (4) Higher vigor levels (C)         (4) Higher vigor levels (C)         (5) Bott fright and the system (C)         (1) Lower body fat (C)         (2) Lower fat oxidation (C)         (3) Better fright and the system (C)         (4) Higher extracellular water (C)         Tension       (2) Higher tool (C)         (4) Higher extracellular water (C)         (5) Worse fright restosterone-to-estradiol ratio (P)         (5) Higher muscle mass (C)         (6) Higher muscle mass (C)         (2) Better frydration (C)         (3) Higher muscle mass (C)         (3) Higher muscle mass (C)         (3) Higher muscle mass (C)         (3) Lower body fat (C)         (4) Higher muscle mass (C)         (5) Lower body fat (C)         (6) Higher muscle mass (C)         (6) Lower body fat (C)         (7) Lower body fat (C)         (6) Lower body fat (C)         (7) Lower body fat (C)         (8) Higher muscle mass (C)         (9) Lower body fat (C)         (9) Lower body fat (C)		<ul><li>(5) Fighter hydration (C)</li></ul>	
SOCIAL AND PSYCHOLOGICAL ASPECTS         Shep quality       (1) Improved overall mode states (C)         Shep quality       (1) Improved overall mode states (C)         Social And Psychological status of the athletes         Vigor       (1) Higher vigor levels (C)         Vigor       (1) Higher vigor levels (C)         Social And Psychological status of the athletes         Social And Psychological status of the athletes         Vigor       (1) Higher vigor levels (C)         Vigor I at a indirect marker of lever muscle mass, increase of body fat, impaired fat oxidation, and less hydration         Social And Composition       (1) Higher testosterone-to-estradici ratio (P)         Measured-to-predicted basa       (1) Higher restosterone-to-estradici ratio (P)         Social Higher muscle mass (C)       (2) Edet rhydration (C)         (2) Higher muscle mass (C)       (3) Edver hydration (C)         (3) Lower loody fat (C)       (3) Higher restosterone-to-estradici ratio (P)         (4) Higher taxidation (C)       (5) Edv		<ul><li>(7) Lower fatigue levels (C)</li></ul>	
Sleep quality       (1) Improved overall mood states (C)       3. Sleep quality may be more important than hormonal levels or eating patterns for the psychological status of the athletes         Libido       (1) Higher vigor levels (C)         Libido       (1) Lover body fat (C)         Vigor       (1) Lover body fat (C)         (2) Lover det accidation (C)       (2) Higher fat accidation (C)         (3) Better hydration (C)       (3) Lover that accidation (C)         (4) Higher extonetilitar water (C)       1. Tension is an indirect marker of less body fat, better fat ocidation, and less hydration (C)         (3) Lover that ocidation (C)       (3) Lover that ocidation (C)         (4) Higher extonetilitar water (C)       1. Tension is an indirect marker of less body fat, better fat ocidation (C)         (5) Lover that ocidation (C)       (3) Lover that ocidation (C)         (6) Lover muscle mass (C)       2) Better hydration (C)         (7) Better hydration (C)       (2) Easter hydration (C)         (8) Higher muscle mass (C)       (3) Higher muscle mass (C)         (9) Lover body fat (C)       (1) Better hydration (C)         (1) Lever body fat (C)       (2) Lover visceral fat (P)         (2) Lover visceral fat (P)       (3) Higher muscle mass (C)         (2) Lover visceral fat (P)       (4) Higher et accidation (C)         (2) Lover visceral fat (P)       (4) Higher fat cocidat	SOCIAL AND PSYCHOLOGICAL	ASPECTS	
(2) Lower depression levels (C)       patterns for the psychological status of the athletes         (4) Higher vigor levels (C)       (4) Higher vigor levels (C)         (1) Lower body fat (C)       (5) Vigor         (2) Higher fat oxidation (C)       (2) Higher fat oxidation (C)         (3) Better hydration (C)       (2) Lower fat oxidation (C)         (4) Higher stot (C)       (2) Lower fat oxidation (C)         (2) Lower fat oxidation (C)       (2) Lower fat oxidation (C)         (4) Uwrse hydration (C)       (2) Lower fat oxidation (C)         (4) Lower mache mass (C)       (2) Lower fat oxidation (C)         (3) Uwrse hydration (C)       (3) Uwrse hydration (C)         (4) Lower mache mass (C)       (2) Better hydration (P)         (3) Higher muscle mass (C)       (3) Higher muscle mass (C)         (3) Higher fat oxidation (P)       (3) Higher muscle mass (C)         (4) Lower body fat (C)       (3) Higher muscle mass (C)         (5) Lower body fat (C)       (3) Lower body fat (C)         (4) Higher fat oxidation (P)       (3) Lower body fat (C)         (5) Lower body fat (C)       (3) Lower body fat (C)         (4) Higher muscle mass (C)       (4) Higher muscle mass (C)         (5) Lower body fat (C)       (5) Lower body fat (C)         (6) Lower oxidation re)       (5) Lower body fat (C)	Sleep quality	(1) Improved overall mood states (C)	1. Sleep quality may be more important than hormonal levels or eating
Since Statigue levels (C)         Libido       (1) Higher vigor levels (C)         Vigor       (1) Lower body fat (C)         2) Higher fat a oxidation (C)       (2) Higher fat a oxidation (C)         (3) Better hydration (C)       (4) Higher vetracellular water (C)         Tension       (1) Higher body fat (C)       1. Tension is an indirect marker of lower muscle mass, increase of body fat, impaired fat oxidation, and less hydration         (3) Worse hydration (C)       (4) Lower muscle mass (C)       1. Tension is an indirect marker of lower muscle mass (C)         BODY METABOLISM AN COMPRESTITION       1. Higher testosterone-to-estradiol ratio (P)       1. The balance between testosterone and estradiol, more than any homone alone, is the major predictor of metabolic rate in male atherets         metabolic ratio       (2) Better hydration (C)       2. Together with the TE ratio, body water and muscle mass are the two major contributors of the metabolic rate, with means that a minimum content of intracellular water is necessary for a proper metabolism         Fat oxidation       (1) Better hydration (C)       3. Body water and muscle mass play the most important roles for fat oxidation, and the second as a possible signaller for the selective fat catabolism, or higher body fat (C)         Fat oxidation       (1) Higher testosterone-to-estradiol ratio (P)       3. Body water and muscle mass play the most important roles for fat oxidation, representation (C)         (2) Lower body fat (C)       (2) Lower body fat (C)       5. Body water and		(2) Lower depression levels (C)	patterns for the psychological status of the athletes
(b) Higher wigh levels (C)         Vigor       (1) Lower body fat (C)         (2) Higher fat oxidation (C)       (2) Higher fat oxidation (C)         (3) Better hydration (C)       (4) Higher extracellular water (C)         Tension       (2) Lower fat oxidation (C)         (3) Worse hydration (C)       (4) Higher extracellular water (C)         (4) Lower muscle mass (C)       (2) Lower fat oxidation (C)         BODY METABOLISM AN COMPOSITION       (1) Higher testosterone-to-estradiol ratio (P)         (3) Higher Hydration (C)       (2) Better hydration (P)         (3) Higher Hydration (C)       (2) Better hydration (C)         (3) Higher Hydration (C)       (2) Better hydration (C)         (3) Higher Hydration (C)       (2) Better hydration (C)         (3) Lower body fat (C)       (3) Higher muscle mass (C)         Fat oxidation       (1) Better hydration (C)         (3) Lower body fat (C)       (2) Better hydration (C)         (3) Lower body fat (C)       (3) Better hydration (C)         (3) Lower body fat (C)       (3) Better hydration (C)         (4) Higher muscle mass (C)       (2) Lower visceral fat (P)         (5) Lower body fat (C)       (3) Lower body fat (C)         (4) Higher fat oxidation (C)       (4) Higher fat oxidation (C)         (5) Lower visceral fat (P)       (5) Lower body f		(3) Less fatigue levels (C)	
Vigor       (1) Lower body fat (C)         Vigor       (2) Higher fat oxidation (C)         (3) Better hydration (C)       (4) Higher extracellular water (C)         Tension       (1) Higher Mydration (C)         (4) Worse hydration (C)       (2) Lower tat oxidation (C)         (4) Worse hydration (C)       (3) Worse hydration (C)         (4) Lower muscle mass (C)       (2) Evert hydration (C)         (5) Worse hydration (C)       (2) Evert hydration (C)         (4) Higher muscle mass (C)       (2) Evert hydration (C)         (3) Higher muscle mass (C)       (2) Evert hydration (C)         (3) Higher muscle mass (C)       (1) Better hydration (C)         (2) Lower body fat (C)       (2) Higher muscle mass (C)         (3) Higher muscle mass (C)       (2) Higher muscle mass (C)         (4) Higher full hydration (C)       (2) Evert hydration (C)         (5) Lower body fat (C)       (2) Higher muscle mass (C)         (4) Higher full hydration (C)       (2) Lower body fat (C)         (5) Lower body fat (C)       (2) Lower hydration (C)         (4) Higher full hydration (C)       (2) Lower viscorial fat (P)         (5) Lower body fat (C)       (2) Lower viscorial fat (P)         (6) Lower body fat (C)       (3) Higher muscle mass (C)         (6) Lower body fat (C)       (4) Higher fat oxidat	Libido	<ul> <li>(4) Higher vigor levels (C)</li> <li>(1) Higher vigor levels (C)</li> </ul>	
Construction       Construction <td< td=""><td>Vigor</td><td>(1) Lower body fat (C)</td><td>1. Vidor is an indirect marker of less body fat, better fat ovidation, and</td></td<>	Vigor	(1) Lower body fat (C)	1. Vidor is an indirect marker of less body fat, better fat ovidation, and
(3)       Better hydration (C) (4)       Higher extracellular water (C)         Tension       (1)       Higher body fat (C) (2)       Lower fat oxidation (C) (3)       I. Tension is an indirect marker of lower muscle mass, increase of body fat, impaired fat oxidation, and less hydration         BODY METABOLISM AN COMPOSITION       (1)       Higher testosterone-to-estradiol ratio (P) (2)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athietes         800Y METABOLISM AN COMPOSITION       (2)       Better hydration (P) (3)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athietes         800Y METABOLISM AN COMPOSITION       (2)       Better hydration (P) (3)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athietes         Fat oxidation       (1)       Better hydration (C) (2)       1. Better hydration (C) (3)       8. Body water and muscle mass play the most important roles for fat oxidation, the first as part of the pathway for fat oxidation, and the second as a possible signalier for the selective fat catabolism, over protein catabolism         Chest-to-waist circumference ratio       (1)       Higher muscle mass (C) (2)       1. Similarly to other metabolic parameters, the TE ratio is the most important direct predictor of the W/C ratio, leading to the popular "V-shape," highly correlated with an androgen phenotype.         Chest-to-waist circumference	Vigoi	(2) Higher fat oxidation (C)	lower edema
(4) Higher extracellular water (C)         Tension       (1) Higher body fat (C)         (2) Lower fat oxidation (C)       (3) Worse hydration (C)         (4) Lower muscle mass (C)       (4) Lower muscle mass (C)         BODY METABOLISM AN COMPOSITOR       (1) Higher testosterone-to-estradiol ratio (P)         (3) Better hydration (C)       (2) Better hydration (C)         (3) Higher muscle mass (C)       (2) Better hydration (C)         (3) Higher muscle mass (C)       (3) Higher muscle mass (C)         Fat oxidation       (1) Better hydration (C)         (2) Higher extracter (C)       (3) Lower body fat (C)         (3) Lower body fat (C)       (3) Lower body fat (C)         (4) Higher extracter (C)       (3) Higher muscle mass (C)         (5) Lower body fat (C)       (3) Lower body fat (C)         (4) Higher extracter (C)       (3) Lower body fat (C)         (5) Lower body fat (C)       (4) Higher festosterone-to-estradiol ratio (P)         (6) Lower visceral fat (P)       (2) Lower visceral fat (P)         (3) Higher muscle mass (C)       (2) Lower visceral fat (P)         (4) Higher fat oxidation (C)       (2) Lower visceral fat (P)         (3) Higher muscle mass (C)       (3) Higher muscle mass (C)         (4) Higher fat oxidation (C)       (4) Higher fat oxidation (C)         (6) Lower visceral fa		(3) Better hydration (C)	
Tension       (1) Higher body fat (C)       1. Tension is an indirect marker of lower muscle mass, increase of body fat, impaired fat oxidation, and less hydration         BODY METABOLISM AN COMPOSITION       (3) Worse hydration (C)       (4) Lower muscle mass (C)         BODY METABOLISM AN COMPOSITION       (2) Better hydration (P)       (3) Higher testosterone-to-estradiol ratio (P)         (3) Higher muscle mass (C)       (3) Higher muscle mass (C)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athletes         Fat oxidation       (1) Better hydration (C)       (2) Higher muscle mass (C)         (2) Higher muscle mass (C)       2. Body water and muscle mass play the most important roles for fat oxidation, and the second as a possible signaller for the selective fat catabolism         Fat oxidation       (1) Higher testosterone-to-estradiol ratio (P)       3. Body water and muscle mass play the most important roles for fat oxidation, and the second as a possible signaller for the selective fat catabolism.         Fat oxidation       (1) Higher testosterone-to-estradiol ratio (P)       3. Body water and fat oxidation, and the second as a possible signaller for the selective fat catabolism.         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)       1. Similarly to other metabolic parameterset, the TE ratio is the most important direct predictor of the WC ratio is the most important direct predictor of the WC ratio is the most important direct predictor of the WC ratio is the most important direct predict		(4) Higher extracellular water (C)	
(2) Lower flydration (C)       (3) Worse hydration (C)         (4) Lower muscle mass (C)       (4) Lower muscle mass (C)         BODY METABOLISM AN COMPOSITION       (1) Higher testosterone-to-estradiol ratio (P)         Measured-to-predicted basal       (1) Higher testosterone-to-estradiol ratio (P)         (3) Higher muscle mass (C)       (3) Higher muscle mass (C)         Fat oxidation       (1) Better hydration (C)         (2) Higher muscle mass (C)       (2) Higher muscle mass (C)         Fat oxidation       (1) Better hydration (C)         (2) Higher muscle mass (C)       (3) Lower body fat (C)         (3) Lower body fat (C)       (3) Lower body fat (C)         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)         ratio       (1) Higher testosterone-to-estradiol ratio (P)         ratio       (3) Lower body fat (C)         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)         ratio       (1) Higher testosterone-to-estradiol ratio (P)         ratio       (2) Lower visceral fat (P)         (4) Higher ratio addation (C)       (4) Higher ratio addation (C)         (5) Lower body fat (C)       (5) Lower body fat (C)         Muscle mass       (1) Late GH response to stimulation (C)         (5) Lower body fat (C)       (5) Better hydration (C)	Tension	(1) Higher body fat (C)	1. Tension is an indirect marker of lower muscle mass, increase of
(a) Lower muscle mass (C)         BODY METABOLISM AN COMPOSITION         Measured-to-predicted basal metabolic ratio       (1) Higher testosterone-to-estradiol ratio (P) (3) Higher muscle mass (C)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athietes         Fat oxidation       (1) Better hydration (C) (2) Higher muscle mass (C)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate, which means that a minimum content of intracellular water is necessary for a proper metabolism         Fat oxidation       (1) Better hydration (C) (2) Higher muscle mass (C)       3. Body water and muscle mass play the most important roles for fat oxidation, the first as part of the pathway for fat oxidation, and the second as a possible signaller for the selective fat catabolism.         Chest-to-waist circumference ratio       (1) Higher testosterone-to-estradiol ratio (P) ratio       1. Similarly to other metabolic parameters, the TE ratio is the most important direct predictor of the WCc ratio, is unknown (5) Better hydration (C) (6) Lower body fat (C)       1. Similarly to other metabolic parameters, the TE ratio is the most important direct predictor of the WCc ratio, leading to the popular "V-shape," highly correlated with an adrogen phenotype.         Muscle mass       (1) Late GH response to stimulation (C) (2) Better hydration (C) (3) Better hydration (C) (3) Better hydration (C) (4) Higher fat oxidation (C) (5) Dower body fat (C)       3. Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle		(2) Lower fat oxidation (C)	body fat, impaired fat oxidation, and less hydration
BODY METABOLISM AN COMPOSITION         Measured-to-predicted basal metabolic ratio       (1) Higher testosterone-to-estradiol ratio (P) (2) Better hydration (P) (3) Higher muscle mass (C)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athletes         Fat oxidation       (1) Better hydration (C) (3) Lower body fat (C)       3. Body water and muscle mass play the most important roles for fat oxidation, the first as part of the pathway for fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, and the second as a possible signaller for the selective fat oxidation, su nknown higher body fat is contributes for a higher W/C ratio         Chest-to-waist circumference ratio       (1) Higher fat oxidation (C) (6) Lower body fat (C)       2. Onche body water is the intracellular water, mostly located within micoytes, rather than adipocytes, this contributes for a higher W/C ratio         Muscle mass       (1) Late GH response to stimulation (C) (2) Late cortisol response to stimulation (C) (3) Better hydration (C) (4) Higher fat oxidation (C) (5) Lower body fat (C)       (2) Lower body fat (C)         Muscle mass       (1) Late GH response to stimulation (C) (3) Better h		(3) Worse hydration (C) (4) Lower muscle mass (C)	
Measured-to-predicted basal metabolic ratio       (1) Higher testosterone-to-estradiol ratio (P)       (3) Higher muscle mass (C)         (2) Better hydration (P)       (3) Higher muscle mass (C)       1. The balance between testosterone and estradiol, more than any hormone alone, is the major predictor of metabolic rate in male athletes         Fat oxidation       (1) Better hydration (C)       2. Together with the T:E ratio, body water and muscle mass are the two major contributors of the metabolic rate, which means that a minimum content of intracellular water is necessary for a proper metabolism         Fat oxidation       (1) Better hydration (C)       3. Body water and muscle mass (C)         (3) Lower body fat (C)       3. Body water and muscle mass play the most important roles for fat oxidation, the first as part of the pathway for fat oxidation, and the second as a possible signaller for the selective fat catabolism, over protein catabolism         Chest-to-waist circumference ratio       (1) Higher testosterone-to-estradiol ratio (P)       3. Higher muscle mass (C)         (3) Higher muscle mass (C)       (3) Higher muscle mass (C)       4. Bigher fat oxidation (C)         (3) Higher muscle mass (C)       (4) Higher fat oxidation (C)       5. Better hydration (C)         (3) Laver body fat (C)       (5) Lower body fat (C)       2. Once body water is the intracellular water, mostly located within micocytes, rather than adipocytes, this contributes for a higher W/C ratio.         (2) Late cortisol response to stimulation (C)       (3) Late cortisol response to stimulation (C)	BODY METABOLISM AN COMPO	SITION	
metabolic ratio       (2) Better hydration (P)       hormone alone, is the major predictor of metabolic rate in male athletes         (3) Higher muscle mass (C)       2. Together with the T:E ratio, body water and muscle mass are the two major contributors of the metabolic rate, which means that a minimum content of intracellular water is necessary for a proper metabolism         Fat oxidation       (1) Better hydration (C)       8. Body water and muscle mass play the most important roles for fat oxidation, the first as part of the pathway for fat oxidation, and the second as a possible signaller for the selective fat catabolism, over protein catabolism         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)       3. Body fat and fat oxidation are inversely correlated; however, whether fat-induced inflammation leads to reduced fat oxidation, or higher body fat is a result from reduced fat oxidation, is unknown         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)       1. Similarly to other metabolic rate, heaving to the popular "V-shape," highly correlated with an androgen phenotype.         Chest-to-waist circumference       (1) Late GH response to stimulation (C)       2. Once body water is the intracellular water, mostly located within micoytes, rather than adipocytes, this contributes for a higher W/C ratio.         Muscle mass       (1) Late GH response to stimulation (C)       3. Better hydration (C)         (2) Late cortisol response to stimulation (C)       (2) Late cortisol response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are	Measured-to-predicted basal	(1) Higher testosterone-to-estradiol ratio (P)	1. The balance between testosterone and estradiol, more than any
<ul> <li>(3) Higher muscle mass (C)</li> <li>athletes</li> <li>2. Together with the T: Tatio, body water and muscle mass are the two major contributors of the metabolic rate, which means that a minimum content of intracellular water is necessary for a proper metabolism</li> <li>Fat oxidation</li> <li>(1) Better hydration (C)</li> <li>(2) Higher muscle mass (C)</li> <li>(3) Lower body fat (C)</li> <li>(3) Lower body fat (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Higher muscle mass (C)</li> <li>(8) Lower body fat (C)</li> <li>(9) Higher muscle mass (C)</li> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat coxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Higher fat oxidation (C)</li> <li>(8) Better hydration (C)</li> <li>(9) Better hydration (C)</li> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Better hydration (C)</li> <li>(8) Better hydration (C)</li> <li>(9) Better hydration (C)</li> <li>(9) Better hydration (C)</li> <li>(1) Late GH response to stimulation (C)</li> <li>(2) Late cortisol response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> </ul>	metabolic ratio	(2) Better hydration (P)	hormone alone, is the major predictor of metabolic rate in male
<ul> <li>2. logether with the 1:E ratio, body water and muscle mass are the two major contributors of the metabolic rate, which means that a minimum content of intracellular water is necessary for a proper metabolism</li> <li>3. Body water and muscle mass play the most important roles for fat oxidation. (2) Higher muscle mass (C)</li> <li>3. Lower body fat (C)</li> <li>3. Body water and muscle mass play the most important roles for fat oxidation, and the oxidation are inversely correlated; however, whether fat-induced inflammation leads to reduced fat oxidation, over protein catabolism</li> <li>4. Body fat and fat oxidation are inversely correlated; however, whether fat-induced inflammation leads to reduced fat oxidation, or higher body fat is a result from reduced fat oxidation, is unknown</li> <li>1. Similarly to other metabolic parameters, the T:E ratio is the most important direct predictor of the W:C ratio, leading to the popular "V-shape," highly correlated with an androgen phenotype.</li> <li>4. Higher fat oxidation (C)</li> <li>(6) Lower body fat (C)</li> <li>2. Once body water is the intracellular water, mostly located within micoytes, rather than adipocytes, this contributes for a higher W/C ratio.</li> <li>3. Muscle mass</li> <li>(1) Late GH response to stimulation (C)</li> <li>(2) Late cortisol response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Evert body fat (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Late GH response to stimulation (C)</li> <li>(8) Better hydration (C)</li> <li>(9) Better hydration (C)</li> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Evert body fat (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Late cortisol response to stimulation (C)</li> <li>(8) Better hydration (C)</li> <li>(9) Euter fat or induction (C)</li> <li>(9) Euter fat or induction (C)</li> <li>(9) Euter fat fat or (C)</li> <li>(1) Late GH response to stimulation (C)&lt;</li></ul>		(3) Higher muscle mass (C)	athletes
Fat oxidation       (1) Better hydration (C)       3. Body water and muscle mass play the most important roles for fat oxidation, the first as part of the pathway for fat oxidation, and the second as a possible signaller for the selective fat catabolism, over protein catabolism         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)       3. Body water and muscle mass to reduced fat oxidation, or higher body fat is a result from reduced fat oxidation, is unknown         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)       1. Similarly to other metabolic parameters, the TE ratio is the most important direct predictor of the W:C ratio, leading to the popular "V-shape," highly correlated with an androgen phenotype.         (4) Higher fat oxidation (C)       (6) Lower body fat (C)       2. Once body water is the intracellular water, mostly located within miceytes, rather than adipocytes, this contributes for a higher W/C ratio         Muscle mass       (1) Late GH response to stimulation (C)       (2) Late cortisol response to stimulation (C)       (3) Better hydration (C)         (2) Late cortisol response to stimulation (C)       (3) Better hydration (C)       (4) Higher fat oxidation (C)       (2) Late cortisol response to stimulation (C)         (3) Better hydration (C)       (3) Euter hydration (C)       (4) Higher fat oxidation (C)       (5) Lower body fat (C)         (5) Lower body fat (C)       (5) Lower body fat (C)       (6) Lower body fat (C)       (7) Atthough the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the			<ol> <li>Together with the T:E ratio, body water and muscle mass are the two major contributors of the metabolic rate, which means that a minimum content of intracellular water is necessary for a proper metabolism</li> </ol>
<ul> <li>(2) Higher muscle mass (C)</li> <li>(3) Lower body fat (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Late GH response to stimulation (C)</li> <li>(8) Late cortisol response to stimulation (C)</li> <li>(9) Late GH response to stimulation (C)</li> <li>(1) Late GH response to stimulation (C)</li> <li>(2) Lower tody fat (C)</li> <li>(3) Higher fat oxidation (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Late GH response to stimulation (C)</li> <li>(7) Late Cortisol response to stimulation (C)</li> <li>(7) Late Cortisol response to stimulation (C)</li> <li>(7) Late GH response to stimulation (C)</li> <li>(7) Late Cortisol response to stimulation (C)</li> <li>(8) Lower body fat (C)</li> </ul> 1. Although the muscle mass is not the lean mass, i.e., the water within muscle are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation. 2. Late hormonal responses, although correlated with muscle mass,	Fat oxidation	(1) Better hydration (C)	3. Body water and muscle mass play the most important roles for fat
<ul> <li>(3) Lower body fat (C)</li> <li>second as a possible signaller for the selective fat catabolism, over protein catabolism</li> <li>Body fat and fat oxidation are inversely correlated; however, whether fat-induced inflammation leads to reduced fat oxidation, or higher body fat is a result from reduced fat oxidation, is unknown</li> <li>Chest-to-waist circumference</li> <li>(1) Higher testosterone-to-estradiol ratio (P)</li> <li>(2) Lower visceral fat (P)</li> <li>(3) Higher muscle mass (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>Muscle mass</li> <li>(1) Late GH response to stimulation (C)</li> <li>(2) Late cortisol response to stimulation (C)</li> <li>(3) Higher fat oxidation (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>Muscle mass</li> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Late cortisol response to stimulation (C)</li> <li>(8) Better hydration (C)</li> <li>(9) Late cortisol response to stimulation (C)</li> <li>(9) Higher fat oxidation (C)</li> <li>(1) Late GH response to stimulation (C)</li> <li>(2) Lower body fat (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Lower body fat (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Late cortisol response to stimulation (C)</li> <li>(8) Higher fat oxidation (C)</li> <li>(9) Late cortisol response to stimulation (C)</li> <li>(9) Lower body fat (C)</li> <li>(9) Lower</li></ul>		(2) Higher muscle mass (C)	oxidation, the first as part of the pathway for fat oxidation, and the
Protein catabolism         4. Body fat and fat oxidation are inversely correlated; however, whether fat-induced inflammation leads to reduced fat oxidation, or higher body fat is a result from reduced fat oxidation, is unknown         Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)         (2) Lower visceral fat (P)       (3) Higher muscle mass (C)         (3) Higher muscle mass (C)       "V-shape," highly correlated with an androgen phenotype.         (4) Higher fat oxidation (C)       Enter hydration (C)         (5) Better hydration (C)       Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle mass       (1) Late GH response to stimulation (C)         (2) Late cortisol response to stimulation (C)       1. Atthough the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       (4) Higher fat oxidation (C)         (5) Lower body fat (C)       2. Late hormonal responses, although correlated with muscle mass, is Lower body fat (C)		(3) Lower body fat (C)	second as a possible signaller for the selective fat catabolism, over
<ul> <li>4. Body fat and fat oxidation are inversely correlated; nowever, whether fat-induced inflammation leads to reduced fat oxidation, or higher body fat is a result from reduced fat oxidation, is unknown</li> <li>Chest-to-waist circumference <ol> <li>(1) Higher testosterone-to-estradiol ratio (P)</li> <li>(2) Lower visceral fat (P)</li> <li>(3) Higher muscle mass (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> </ol> </li> <li>Muscle mass <ol> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Better hydration (C)</li> <li>(6) Lower body fat (C)</li> </ol> </li> <li>Muscle mass <ol> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Lower body fat (C)</li> </ol> </li> </ul> <li>Muscle mass <ol> <li>(1) Late GH response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Lower body fat (C)</li> </ol> </li> <li>Muscle mass <ol> <li>(1) Late off response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Lower body fat (C)</li> </ol> </li>			protein catabolism
Chest-to-waist circumference       (1) Higher testosterone-to-estradiol ratio (P)       (3) Higher muscle mass (C)       (4) Higher fat oxidation (C)         (3) Higher fat oxidation (C)       (4) Higher fat oxidation (C)       (5) Lower body fat (C)       (2) Lower visceral fat (P)         Muscle mass       (1) Late GH response to stimulation (C)       (2) Lower body fat (C)       (3) Higher fat oxidation (C)         Muscle mass       (1) Late GH response to stimulation (C)       (2) Late cortisol response to stimulation (C)       (3) Better hydration (C)         Muscle mass       (1) Late GH response to stimulation (C)       (3) Better hydration (C)       (3) Higher fat oxidation (C)         (4) Higher fat oxidation (C)       (4) Higher fat oxidation (C)       (5) Lower body fat (C)       (6) Lower body fat (C)			<ol> <li>Body fat and fat oxidation are inversely correlated; nowever, whether fat-induced inflammation leads to reduced fat oxidation, or</li> </ol>
Chest-to-waist circumference ratio       (1) Higher testosterone-to-estradiol ratio (P)       (2) Lower visceral fat (P)       (3) Higher muscle mass (C)         (3) Higher muscle mass (C)       (4) Higher fat oxidation (C)       (5) Better hydration (C)       (6) Lower body fat (C)         (6) Lower body fat (C)       (7) Late GH response to stimulation (C)       (2) Late cortisol response to stimulation (C)       (3) Higher fat oxidation (C)         Muscle mass       (1) Late GH response to stimulation (C)       (2) Late cortisol response to stimulation (C)       (3) Better hydration (C)         (4) Higher fat oxidation (C)       (2) Lower body fat (C)       (3) Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle mass       (1) Late GH response to stimulation (C)       (2) Late cortisol response to stimulation (C)         (3) Better hydration (C)       (3) Better hydration (C)       (4) Higher fat oxidation (C)         (3) Better hydration (C)       (3) Better hydration (C)       (4) Higher fat oxidation (C)         (5) Lower body fat (C)       (5) Lower body fat (C)       (2) Late cortisol responses, sith and predicts fat oxidation.			higher body fat is a result from reduced fat oxidation, of
ratio (2) Lower visceral fat (P) (3) Higher muscle mass (C) (4) Higher fat oxidation (C) (5) Better hydration (C) (6) Lower body fat (C) (7) Late GH response to stimulation (C) (2) Late cortisol response to stimulation (C) (3) Better hydration (C) (4) Higher fat oxidation (C) (5) Lower body fat (C) (7) Late GH response to stimulation (C) (7) Late GH response to stimulation (C) (7) Late ortisol responses, although correlated with muscle mass, are probably two consequences of a same common factor.	Chest-to-waist circumference	(1) Higher testosterone-to-estradiol ratio (P)	1. Similarly to other metabolic parameters, the T:E ratio is the most
(3) Higher muscle mass (C)       "V-shape," highly correlated with an androgen phenotype.         (4) Higher fat oxidation (C)       2. Once body water is the intracellular water, mostly located within miccytes, rather than adipocytes, this contributes for a higher W/C ratio         (5) Better hydration (C)       7         (6) Lower body fat (C)       3. Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle mass       (1) Late GH response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       (2) Late cortisol response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       2. Late hormonal responses, although correlated with muscle mass, are probably two consequences of a same common factor.	ratio	(2) Lower visceral fat (P)	important direct predictor of the W:C ratio, leading to the popular
(4) Higher fat oxidation (C)       2. Once body water is the intracellular water, mostly located within micoytes, rather than adipocytes, this contributes for a higher W/C ratio         (5) Better hydration (C)       inicoytes, rather than adipocytes, this contributes for a higher W/C ratio         (6) Lower body fat (C)       3. Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle mass       (1) Late GH response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       2. Late hormonal responses, although correlated with muscle mass, are probably two consequences of a same common factor.		(3) Higher muscle mass (C)	"V-shape," highly correlated with an androgen phenotype.
(5) Better hydration (C)       milocytes, rather than adipocytes, this contributes for a higher w/C ratio         (6) Lower body fat (C)       ratio         3. Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle mass       (1) Late GH response to stimulation (C)         (2) Late cortisol response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       2. Late hormonal responses, although correlated with muscle mass, is are probably two consequences of a same common factor.		(4) Higher fat oxidation (C)	2. Once body water is the intracellular water, mostly located within
(b) Lower body lat (c)       1 late         Muscle mass       (1) Late GH response to stimulation (C)       3. Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively         Muscle mass       (1) Late GH response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       2. Late hormonal responses, although correlated with muscle mass, i.e. probably two consequences of a same common factor.		(5) Better hydration (C) (6) Lower body fat (C)	miccytes, rather than adipocytes, this contributes for a higher W/C
Muscle mass       (1) Late GH response to stimulation (C)       1. Although the muscle mass is not the lean mass, i.e., the water within muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.         (2) Late cortisol response to stimulation (C)       (3) Better hydration (C)       a muscle anabolic environment, and predicts fat oxidation.         (4) Higher fat oxidation (C)       (5) Lower body fat (C)       Late hormonal responses, although correlated with muscle mass, are probably two consequences of a same common factor.		(b) Lower body lat (b)	<ol> <li>Muscle mass and body fat are expectedly directly and inversely correlated with W/C ratio, respectively</li> </ol>
<ul> <li>(2) Late cortisol response to stimulation (C)</li> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Lower body fat (C)</li> <li>(6) Lower body fat (C)</li> <li>(7) Lower body fat (C)</li> <li>(8) muscles are not accounted, the presence of body water helps provide a muscle anabolic environment, and predicts fat oxidation.</li> <li>(9) Lower body fat (C)</li> <li>(10) Lower body fat (C)</li> <li>(11) Lower body fat (C)</li> <li>(12) Lower body fat (C)</li> <li>(13) Lower body fat (C)</li> <li>(14) Lower body fat (C)</li> <li>(15) Lower body fat (C)</li> <li>(15) Lower body fat (C)</li> <li>(15) Lower body fat (C)</li> <li>(16) Lower body fat (C)</li> <li>(17) Lower body fat (C)<!--</td--><td>Muscle mass</td><td>(1) Late GH response to stimulation (C)</td><td>1. Although the muscle mass is not the lean mass, i.e., the water within</td></li></ul>	Muscle mass	(1) Late GH response to stimulation (C)	1. Although the muscle mass is not the lean mass, i.e., the water within
<ul> <li>(3) Better hydration (C)</li> <li>(4) Higher fat oxidation (C)</li> <li>(5) Lower body fat (C)</li> <li>(6) a muscle anabolic environment, and predicts fat oxidation.</li> <li>(7) Lower body fat (C)</li> <li>(8) a muscle anabolic environment, and predicts fat oxidation.</li> <li>(9) Lower body fat (C)</li> <li>(10) a muscle anabolic environment, and predicts fat oxidation.</li> <li>(11) Lower body fat (C)</li> <li>(2) Late hormonal responses, although correlated with muscle mass, are probably two consequences of a same common factor.</li> </ul>		(2) Late cortisol response to stimulation (C)	muscles are not accounted, the presence of body water helps provide
(4) Fighter factorization (5) (5) Lower body fat (C) (5) Lower body		(3) Better hydration (C)	a muscle anabolic environment, and predicts fat oxidation.
		(5) Lower body fat (C)	are probably two consequences of a same common factor.

(Continued)

TABLE 4 | Continued

Parameter	Markers	Potential implication(s)
Fat mass	<ol> <li>(1) Improved overall mood states (C)</li> <li>(2) Higher vigor levels (C)</li> <li>(3) Decreased hydration (C)</li> <li>(4) Lower muscle mass (C)</li> <li>(5) Decreased fat oxidation (C)</li> </ol>	<ol> <li>Worse psychological moods may be indicators of less healthier environment, that naturally tends to save fat storage and catabolize muscle mass.</li> <li>All correlated body composition parameters are accordingly.</li> </ol>
Extracellular water (= edema)	<ol> <li>Worse hydration (C)</li> <li>Lower muscle mass (C)</li> <li>Increased fat mass (C)</li> </ol>	<ol> <li>The more proper hydration, the less edema; however, what determines the destination of the ingested water is the metabolic environment, not the amount of water intake</li> <li>Fat mass, likely through inflammatory processes, may induce edema, although we did not find prediction relationship.</li> </ol>

P, Prediction; C, Correlation; T:E, Testosterone-to-estradiol; W:C, Chest-to-waist circumference.

present study show that further studies should not evaluate each aspect separately, as this is unlikely to provide answers to important questions.

## DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

## **ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethical committee of the Federal University of São Paulo (Approval Number: 1093965). The patients/participants provided their written informed consent to participate in this study.

## REFERENCES

- Karjalainen JJ, Kiviniemi AM, Hautala AJ, Piira OP, Lepojärvi ES, Perkiömäki JS, et al. Effects of physical activity and exercise training on cardiovascular risk in coronary artery disease patients with and without type 2 diabetes. *Diabetes Care*. (2015) 38:706–15. doi: 10.2337/dc14-2216
- Myers J, McAuley P, Lavie CJ, Despres JP, Arena R, Kokkinos P. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. *Prog Cardiovasc Dis.* (2015) 57:306–14. doi: 10.1016/j.pcad.2014.09.011
- McKenzie F McKenzie F, Biessy C, Ferrari P, Freisling H, Rinaldi S, et al. Healthy lifestyle and risk of cancer in the european prospective investigation into cancer and nutrition cohort study. *Medicine*. (2016) 95:e2850. doi: 10.1097/MD.00000000002850
- Zhao G, Li C, Ford ES, Fulton JE, Carlson SA, Okoro CA, et al. Leisuretime aerobic physical activity, muscle-strengthening activity and mortality risks among US adults: the NHANES linked mortality study. *Br J Sports Med.* (2014) 48:244–9. doi: 10.1136/bjsports-2013-092731
- Carlson SA, Adams EK, Yang Z, Fulton JE. Percentage of deaths associated with inadequate physical activity in the United States. *Prev Chronic Dis.* (2018) 15:E38. doi: 10.5888/pcd18.170354
- Loprinzi PD, Addoh O, Wong Sarver N, Espinoza I, Mann JR. Cross-sectional association of exercise, strengthening activities, and cardiorespiratory fitness on generalized anxiety, panic and depressive symptoms. *Postgrad Med.* (2017) 129:676–85. doi: 10.1080/00325481.2017.1336054
- 7. Machado S, Filho ASS, Wilbert M, Barbieri G, Almeida V, Gurgel A, et al. Physical exercise as stabilizer for alzheimer's disease cognitive

## **AUTHOR CONTRIBUTIONS**

FC and CK developed the central idea of the present manuscript. FC performed the tests of the EROS study, compilated the data, analyzed the results, and participated in the discussions. CK actively participated in the discussion, supervised and reviewed the results, helped with the final version of the manuscript, and gave the last word before the submission. All authors have read and approved the manuscript.

## ACKNOWLEDGMENTS

We acknowledge the Department of Sports Medicine and the Division of Endocrinology, Department of Medicine, from the Federal University of São Paulo, DASA Laboratórios da América, and Corpometria Insitute.

decline: current status. *Clin Pract Epidemiol Ment Health.* (2017) 13:181–4. doi: 10.2174/1745017901713010181

- Warburton DER, Bredin SSD. Health benefits of physical activity: a systematic review of current systematic reviews. *Curr Opin Cardiol.* (2017) 32:541–56. doi: 10.1097/HCO.00000000000437
- Maessen MF Eijsvogels TM, Stevens G, van Dijk AP, Hopman MT. Benefits of lifelong exercise training on left ventricular function after myocardial infarction. *Eur J Prev Cardiol.* (2017) 24:1856–66. doi: 10.1177/2047487317728765
- Piepoli MF, Villani GQ. Lifestyle modification in secondary prevention. Eur J Prev Cardiol. (2017) 24(3\_suppl):101-7. doi: 10.1177/2047487317 703828
- Porter C, Reidy PT, Bhattarai N, Sidossis LS, Rasmussen BB. Resistance exercise training alters mitochondrial function in human skeletal muscle. *Med Sci Sports Exerc.* (2015) 47:1922–31. doi: 10.1249/MSS.00000000000605
- Lindgren M, Alex C, Shapiro PA, McKinley PS, Brondolo EN, Myers MM, et al. Effects of aerobic conditioning on cardiovascular sympathetic response to and recovery from challenge. *Psychophysiology*. (2013) 50:963– 73. doi: 10.1111/psyp.12078
- Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM, et al. IOC consensus statement: dietary supplements and the high-performance athlete. Br J Sports Med. (2018) 52:439–55. doi: 10.1136/bjsports-2018-099027
- Chennaoui M, Arnal PJ, Sauvet F, Léger D. Sleep and exercise: a reciprocal issue? Sleep Med Rev. (2015) 20:59–72. doi: 10.1016/j.smrv.2014.06.008
- 15. Meeusen, R, Duclos, M, Foster, C, European College of Sport Science, American College of Sports Medicine. Prevention, diagnosis, and treatment

of the overtraining syndrome: joint consensus statement of the european college of sport science and the american college of sports medicine. *Med Sci Sports Exerc.* (2013) 45:186–205. doi: 10.1249/MSS.0b013e3182 79a10a

- Kreher, JB, Schwartz, JB. Overtraining syndrome: a practical guide. Sports Health. (2012) 4:128–38. doi: 10.1177/1941738111434406
- Rietjens GJ, Kuipers H, Adam JJ, Saris WH, van Breda E, van Hamont D, et al. Physiological, biochemical and psychological markers of strenuous training-induced fatigue. *Int J Sports Med.* (2005) 26:16–26. doi: 10.1055/s-2004-817914
- Cadegiani FA, Kater CE. Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: results of the EROS study (EROS-PROFILE). J Sports Sci. (2018) 36:1902–10. doi: 10.1080/02640414.2018.1424498
- Cadegiani FA, Kater CE. Hypothalamic-pituitary-adrenal (HPA) axis functioning in overtraining syndrome: findings from Endocrine and Metabolic Responses on Overtraining Syndrome (EROS) - EROS-HPA axis. *Sports Med Open*. (2017) 3:45. doi: 10.1186/s40798-017-0113-0
- Cadegiani FA, Kater CE. Hormonal responses to a non-exercise stress test in athletes with overtraining syndrome: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) - EROS-STRESS. *J Sci Med Sport*. (2018) 21:648–53. doi: 10.1016/j.jsams.2017.10.033
- Cadegiani FA, Kater CE. Basal hormones and biochemical markers as predictors of OTS: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) study - EROS-BASAL. J Athl Train. (2019) 54:906–14. doi: 10.4085/1062-6050-148-18
- Cadegiani FA, Kater CE, Gazola M. Clinical and biochemical characteristics of high-intensity functional training (HIFT) and overtraining syndrome: findings from the EROS study (The EROS-HIFT). J Sports Sci. (2019) 3:1296–307. doi: 10.1080/02640414.2018.1555912
- 23. Cadegiani FA, Kater CE. Novel insights of overtraining syndrome discovered from the EROS study. *BMJ Open Sport Exerc Med.* (2019) 5:e000542. doi: 10.1136/bmjsem-2019-000542
- Cadegiani FA, Kater CE. Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study. BMC Sports Sci Med Rehabil. (2019) 11:21. doi: 10.1186/s13102-019-0132-x
- Shortell T. An Introduction to Data Analysis & Presentation. Available online at: http://www.shortell.org/book/chap18.html (accessed November 9<sup>,</sup> 2019).
- McSeveny A, Conway R, Wilkes S, Smith M. Guideline for Interpreting Correlation Coefficient by Ith Phanny To accompany: International Mathematics For the Middle Year 5. Pearson Australia 2009 ITH PHANNY.
- 27. Moore DS, Notz WI, Flinger MA. *The Basic Practice of Statistics, 6th Edn.*. New York, NY: W. H. Freeman and Company (2013).
- Rahim A, O'Neill P, Shalet SM. The effect of body composition on hexarelininduced growth hormone release in normal elderly subjects. *Clin Endocrinol.* (1998) 49:659–64. doi: 10.1046/j.1365-2265.1998.00586.x
- 29. van Koeverden ID, de Bakker M, Haitjema S, van der Laan SW, de Vries JPM, Hoefer IE, et al. Testosterone to oestradiol ratio reflects systemic and plaque inflammation and predicts future cardiovascular events in men with severe atherosclerosis. *Cardiovasc Res.* (2019) 115:453–62. doi: 10.1093/cvr/cvy188
- 30. Chan YX, Knuiman MW, Hung J, Divitini ML, Handelsman DJ, Beilby JP, et al. Testosterone, dihydrotestosterone and estradiol are differentially associated with carotid intima-media thickness and the presence of carotid plaque in men with and without coronary artery disease. *Endocr J.* (2015) 62:777–86. doi: 10.1507/endocrj.EJ15-0196
- Aguirre LE, Colleluori G, Fowler KE, Jan IZ, Villareal K, Qualls C, et al. High aromatase activity in hypogonadal men is associated with higher spine bone mineral density, increased truncal fat and reduced lean mass. *Eur J Endocrinol.* (2015) 173:167–74. doi: 10.1530/EJE-14-1103
- Xu X, Wang L, Luo D, Zhang M, Chen S, Wang Y, et al. Effect of testosterone synthesis and conversion on serum testosterone levels in obese men. *Horm Metab Res.* (2018) 50:661–70. doi: 10.1055/a-0658-7712
- Arevalo MA, Azcoitia I, Garcia-Segura LM. The neuroprotective actions of oestradiol and oestrogen receptors. *Nat Rev Neurosci.* (2015) 16:17–29. doi: 10.1038/nrn3856
- Russell N, Grossmann M. Mechanisms in endocrinology: estradiol as a male hormone. *Eur J Endocrinol.* (2019) 1:EJE-18–1000.R2. doi: 10.1530/EJE-18-1000

- Charrière N, Miles-Chan JL, Montani JP, Dulloo AG. Water-induced thermogenesis and fat oxidation: a reassessment. *Nutr Diabetes*. (2015) 5:e190. doi: 10.1038/nutd.2015.41
- Purdom T, Kravitz L, Dokladny K, Mermier C. Understanding the factors that effect maximal fat oxidation. J Int Soc Sports Nutr. (2018) 15:3. doi: 10.1186/s12970-018-0207-1
- Jequier E, Constant F. Water as an essential nutrient: the physiological basis of hydration. *Eur J Clin Nutr.* (2018) 64:115–23. doi: 10.1038/ejcn. 2009.111
- Cadegiani FA, Kater CE. Enhancement of hypothalamic-pituitary activity in male athletes: evidence of a novel hormonal mechanism of physical conditioning. *BMC Endoc Dis.* (2019) 1:117. doi: 10.1186/s12902-019-0443-7
- Oosterholt BG, Maes JH, Van der Linden D, Verbraak MJ, Kompier MA. Burnout and cortisol: evidence for a lower cortisol awakening response in both clinical and non-clinical burnout. J Psychosom Res. (2015) 78:445–51. doi: 10.1016/j.jpsychores.2014.11.003
- Grossi G, Perski A, Ekstedt M, Johansson T, Lindström M, Holm K. The morning salivary cortisol response in burnout. J Psychosom Res. (2005) 59:103–11. doi: 10.1016/j.jpsychores.2005.02.009
- Sjörs A, Ljung T, Jonsdottir IH. Long-term follow-up of cortisol awakening response in patients treated for stress-related exhaustion. *BMJ Open.* (2012) 2:e001091. doi: 10.1136/bmjopen-2012-001091
- Nater UM, Maloney E, Boneva RS, Gurbaxani BM, Lin JM, Jones JF, et al. Attenuated morning salivary cortisol concentrations in a population based study of persons with chronic fatigue syndrome and well controls. J Clin Endocrinol Metab. (2008) 93:703–9. doi: 10.1210/jc.2007-1747
- Stalder T, Kirschbaum C, Kudielka BM, Adam EK, Pruessner JC, Wust S, et al. Assessment of the cortisol awakening response: expert consensus guidelines. *Psychoneuroendocrinology*. (2016) 63:414–32. doi: 10.1016/j.psyneuen.2015.10.010
- Elder GJ, Wetherell MA, Barclay NL, Ellis JG. The cortisol awakening response–applications and implications for sleep medicine. *Sleep Med Rev.* (2014) 18:215–24. doi: 10.1016/j.smrv.2013.05.001
- Clow A, Hucklebridge F, Stalder T, Evans P, Thorn L. The cortisol awakening response: more than a measure of HPA axis function. *Neurosci Biobehav Rev.* (2010) 35:97–103. doi: 10.1016/j.neubiorev.2009.12.011
- 46. Smyth N, Thorn L, Hucklebridge F, Evans P, Clow A. Detailed time course of the cortisol awakening response in healthy participants. *Psychoneuroendocrinology*. (2015) 62:200–3. doi: 10.1016/j.psyneuen.2015.08.011
- Wilhelm I, Born J, Kudielka BM, Schlotz W, Wust S. Is the cortisol awakening rise a response to awakening? *Psychoneuroendocrinology*. (2007) 32:358–66. doi: 10.1016/j.psyneuen.2007.01.008
- Zhang J, Ma RC, Kong AP, So WY, Li AM, Lam SP, et al. Relationship of sleep quantity and quality with 24-h urinary catecholamines and salivary awakening cortisol in healthy middle-aged adults. *Sleep*. (2011) 34:225–33. doi: 10.1093/sleep/34.2.225
- Pires GN, Bezerra AG, Tufik S, Andersen ML. Effects of acute sleep deprivation on state anxiety levels: a systematic review and meta-analysis. *Sleep Med.* (2016) 24:109–18. doi: 10.1016/j.sleep.2016.07.019
- Obasi EM, Chen TA, Cavanagh L, Smith BK, Wilborn KA, McNeill LH, et al. Depression, perceived social control, and hypothalamic-pituitaryadrenal axis function in African-American adults. *Health Psychol.* (2019). doi: 10.1037/hea0000812. [Epub ahead of print].
- Cadegiani FA, Kater CE. Adrenal fatigue does not exist: a systematic review. BMC Endocr Disord. (2016) 16:48. doi: 10.1186/s12902-016-0128-4
- Abu-Samak MS, Mohammad BA, Abu-Taha MI, Hasoun LZ, Awwad SH. Associations between sleep deprivation and salivary testosterone levels in male university students: a prospective cohort study. *Am J Mens Health*. (2018) 12:411–9. doi: 10.1177/1557988317735412
- Lee DS, Choi JB, Sohn DW. Impact of sleep deprivation on the hypothalamicpituitary-gonadal axis and erectile tissue. J Sex Med. (2019) 16:5–16. doi: 10.1016/j.jsxm.2018.10.014
- Arnal PJ, Drogou C, Sauvet F, Regnauld J, Dispersyn G, Faraut B, et al. Effect of sleep extension on the subsequent testosterone, cortisol and prolactin responses to total sleep deprivation and recovery. *J Neuroendocrinol.* (2016) 28:12346. doi: 10.1111/jne.12346

- Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med. (2007) 3:519–28. doi: 10.1080/15402000701244445
- 56. Pérez-Fuentes MDC, Molero Jurado MDM, Simón Márquez MDM, Barragán Martín AB, Gázquez Linares JJ. Emotional effects of the duration, efficiency, and subjective quality of sleep in healthcare personnel. *Int J Environ Res Public Health.* (2019) 16:E3512. doi: 10.3390/ijerph161 93512
- Park YK, Kim JH, Choi SJ, Kim ST, Joo EY. Altered regional cerebral blood flow associated with mood and sleep in shift workers: cerebral perfusion magnetic resonance imaging study. J Clin Neurol. (2019) 15:438– 47. doi: 10.3988/jcn.2019.15.4.438
- Schwarz J, Axelsson J, Gerhardsson A, Tamm S, Fischer H, Kecklund G, et al. Mood impairment is stronger in young than in older adults after sleep deprivation. J Sleep Res. (2019) 28:e12801. doi: 10.1111/jsr.12801
- Lo JC, Ong JL, Leong RL, Gooley JJ, Chee MW. Cognitive performance, sleepiness, and mood in partially sleep deprived adolescents: the need for sleep study. *Sleep*. (2016) 39:687–98. doi: 10.5665/sleep.5552
- Chaput JP, Dutil C, Sampasa-Kanyinga H. Sleeping hours: what is the ideal number and how does age impact this? *Nat Sci Sleep.* (2018) 10:421–30. doi: 10.2147/NSS.S163071
- Grandner MA, Drummond SP. Who are the long sleepers? Towards an understanding of the mortality relationship. *Sleep Med Rev.* (2007) 11:341– 60. doi: 10.1016/j.smrv.2007.03.010
- Popkin BM, D'Anci KE, Rosenberg IH. Water, hydration, and health. Nutr Rev. (2010) 68:439–58. doi: 10.1111/j.1753-4887.2010.00304.x
- Armstrong LE. Challenges of linking chronic dehydration and fluid consumption to health outcomes. *Nutr Rev.* (2012) 70(Suppl 2):S121–7. doi: 10.1111/j.1753-4887.2012.00539.x
- Liska D, Mah E, Brisbois T, Barrios PL, Baker LB, Spriet LL. Narrative review of hydration and selected health outcomes in the general population. *Nutrients*. (2019) 11:E70. doi: 10.3390/nu11010070
- El-Sharkawy AM, Sahota O<sup>1</sup>, Lobo DN. Acute and chronic effects of hydration status on health. *Nutr Rev.* (2015) 73(Suppl 2):97–109l. doi: 10.1093/nutrit/nuv038
- Shirreffs SM. Markers of hydration status. Eur J Clin Nutr. (2003) 57:S6-9. doi: 10.1038/sj.ejcn.1601895
- Svendsen IS, Killer SC, Gleeson M. Influence of hydration status on changes in plasma cortisol, leukocytes, and antigen-stimulated cytokine production by whole blood culture following prolonged exercise. *ISRN Nutr.* (2014) 2014:561401. doi: 10.1155/2014/561401
- Penkman MA, Field CJ, Sellar CM, Harber VJ, Bell GJ. Effect of hydration status on high-intensity rowing performance and immune function. *Int J Sports Physiol Perform*. (2008) 3:531–46. doi: 10.1123/ijspp.3.4.531
- Borgman MA, Zaar M, Aden JK, Schlader ZJ, Gagnon D, Rivas E, et al. Hemostatic responses to exercise, dehydration, and simulated bleeding in heat-stressed humans. *Am J Physiol Regul Integr Comp Physiol.* (2019) 316:R145–56. doi: 10.1152/ajpregu.00223.2018
- Roh HT, Cho SY, So WY, Paik IY, Suh SH. Effects of different fluid replacements on serum HSP70 and lymphocyte DNA damage in college athletes during exercise at high ambient temperatures. *J Sport Health Sci.* (2016) 5:448–55. doi: 10.1016/j.jshs.2015.09.007
- Hom LL, Lee EC, Apicella JM, Wallace SD, Emmanuel H, Klau JF, et al. Eleven days of moderate exercise and heat exposure induces acclimation without significant HSP70 and apoptosis responses of lymphocytes in college-aged males. *Cell Stress Chaperones*. (2012) 17:29–39. doi: 10.1007/s12192-011-0283-5
- 72. Kim YN, Shin HS. Relationships of total lymphocyte count and subpopulation lymphocyte counts with the nutritional status in patients undergoing hemodialysis/peritoneal dialysis. *Kosin Med J.* (2017) 32:58–71. doi: 10.7180/kmj.2017.32.1.58
- Altunayoglu Cakmak V, Ozsu S, Gulsoy A, Akpinar R, Bulbul Y. The significance of the relative lymphocyte count as an independent predictor of cardiovascular disease in patients with obstructive sleep apnea syndrome. *Med Princ Pract.* (2016) 25:455–60. doi: 10.1159/000447697
- Dmitrieva NI, Burg MB. Elevated sodium and dehydration stimulate inflammatory signaling in endothelial cells and promote atherosclerosis. *PLoS One.* (2015) 10:e0128870. doi: 10.1371/journal.pone.0128870

- Mitchell JB, Dugas JP, McFarlin BK, Nelson MJ. Effect of exercise, heat stress, and hydration on immune cell number and function. *Med Sci Sports Exerc.* (2002) 34:1941–50. doi: 10.1097/00005768-200212000-00013
- Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets*. (2015) 26:680–1. doi: 10.3109/09537104.2014.979340
- Ye GL, Chen Q, Chen X, Liu YY, Yin TT, Meng QH, et al. The prognostic role of platelet-to-lymphocyte ratio in patients with acute heart failure: a cohort study. *Sci Rep.* (2019) 9:10639. doi: 10.1038/s41598-019-47143-2
- Akboga MK, Canpolat U, Yayla C, Ozcan F, Ozeke O, Topaloglu S, et al. Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease. *Angiology*. (2016) 67:89–95. doi: 10.1177/0003319715583186
- 79. Liaw FY, Huang CF, Chen WL, Wu LW, Peng TC, Chang YW, et al. Higher platelet-to-lymphocyte ratio increased the risk of sarcopenia in the community-dwelling older adults. *Sci Rep.* (2017) 7:16609. doi: 10.1038/s41598-017-16924-y
- Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD. The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. *Ann Lab Med.* (2019) 39:345–57. doi: 10.3343/alm.2019.39.4.345
- Eccles R, Mallefet P. Observational study of the effects of upper respiratory tract infection on hydrationstatus. *Multidiscip Respir Med.* (2019) 14:36. doi: 10.1186/s40248-019-0200-9
- Yang DF, Shen YL, Wu C, Huang YS, Lee PY, Er NX, et al. Sleep deprivation reduces the recovery of muscle injury induced by high-intensity exercise in a mouse model. *Life Sci.* (2019) 235:116835. doi: 10.1016/j.lfs.2019.116835
- Wang JP, Chi RF, Wang K, Ma T, Guo XF, Zhang XL, et al. Exp oxidative stress impairs myocyte autophagy, resulting in myocyte hypertrophy. *Physiology*. (2018) 103:461–72. doi: 10.1113/EP086650
- Ng TP, Lu Y, Choo RWM, Tan CTY, Nyunt MSZ, Gao Q, et al. Dysregulated homeostatic pathways in sarcopenia among frail older adults. *Aging Cell*. (2018) 17:e12842. doi: 10.1111/acel.12842
- Berr CM, Stieg MR, Deutschbein T, Quinkler M, Schmidmaier R, Osswald A, et al. Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. *Eur J Endocrinol.* (2017) 176:737–46. doi: 10.1530/EJE-16-0689
- Solomon AM, Bouloux PM. Modifying muscle mass—the endocrine perspective. J Endocrinol. (2006) 191:349–60. doi: 10.1677/joe.1.06837
- Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. *Nat Rev Endocrinol.* (2012) 8:457–65. doi: 10.1038/nrendo.2012.49
- Lemche E, Chaban OS, Lemche AV. Neuroendorine and epigenetic mechanisms subserving autonomic imbalance and HPA dysfunction in the metabolic syndrome. *Front Neurosci.* (2016) 10:142. doi: 10.3389/fnins.2016.00142
- Romanello V, Sandri M. Mitochondrial quality control and muscle mass maintenance. *Front Physiol.* (2015) 6:422. doi: 10.3389/fphys.2015.00422
- Peng K, Pan Y, Li J, Khan Z, Fan M, Yin H, et al. 11beta-hydroxysteroid dehydrogenase type 1(11beta-HSD1) mediates insulin resistance through JNK activation in adipocytes. *Sci Rep.* (2016) 6:37160. doi: 10.1038/srep37160
- Chapman K, Holmes M, Seckl J. 11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. *Physiol Rev.* (2013) 93:1139–206. doi: 10.1152/physrev.00020.2012
- Hu F, Liu F. Mitochondrial stress: a bridge between mitochondrial dysfunction and metabolic diseases? *Cell Signal.* (2011) 23:1528–33. doi: 10.1016/j.cellsig.2011.05.008
- Brennan K, Gallo S, Slavin M, Herrick J, Jonge LD. Water Consumption Increases Resting Fat Oxidation. New Orleans, LA: Poster presentation at Obesity Week 2016 (2016).
- Stookey JJD. Negative, null and beneficial effects of drinking water on energy intake, energy expenditure, fat oxidation and weight change in randomized trials: a qualitative review. *Nutrients*. (2016) 8:19. doi: 10.3390/nu8010019
- Keller U, Szinnai G, Bilz S, Berneis K. Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. *Eur J Clin Nutr.* (2003) 57 (Suppl 2):S69–74. doi: 10.1038/sj.ejcn.1601904
- Boschmann M, Steiniger J, Franke G, Birkenfeld AL, Luft FC, Jordan J. Water drinking induces thermogenesis through osmosensitive mechanisms. J Clin Endocrinol Metab. (2007) 92:3334–7. doi: 10.1210/jc.2006-1438

- Boschmann M, Steiniger J, Hille U, Tank J, Adams F, Sharma AM, et al. Water-induced thermogenesis. J Clin Endocrinol Metab. (2003) 88:6015–9. doi: 10.1210/jc.2003-030780
- Dennis EA, Dengo AL, Comber DL, Flack KD, Savla J, Davy KP, et al. Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. *Obesity*. (2010) 18:300–7. doi: 10.1038/oby.2009.235
- González-Alonso J, Calbet JA, Nielsen B. Muscle blood flow is reduced with dehydration during prolonged exercise in humans. *J Physiol.* (1998) 513(Pt 3):895–905. doi: 10.1111/j.1469-7793.1998.895ba.x
- 100. Klaas RW, Smeets A, Lejeune PM, Wouters-Adriaens MPE, Margriet S Westerterp P, et al. Dietary fat oxidation as a function of body fat. Am J Clin Nutr. (2008) 87:132–5. doi: 10.1093/ajcn/87.1.132
- 101. Zurlo F, Lillioja S, Del Puente AE, Nyomba BL, Raz I, Saad MF, et al. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. *Am J Physiol.* (1990) 259:E650–7. doi: 10.1152/ajpendo.1990.259.5.E650
- 102. MacKenzie-Shalders KL, Byrne NM, King NA, Slater GJ. Are increases in skeletal muscle mass accompanied by changes to resting metabolic rate in rugby athletes over a pre-season training period? *Eur J Sport Sci.* (2019) 19:885–92. doi: 10.1080/17461391.2018.1561951
- McPherron AC, Guo T, Bond ND, Gavrilova O. Increasing muscle mass to improve metabolism. *Adipocyte*. (2013) 2:92–8. doi: 10.4161/adip.22500
- 104. Müller MJ, Langemann D, Gehrke I, Later W, Heller M, Glüer CC, et al. Effect of constitution on mass of individual organs and their association with metabolic rate in humans–a detailed view on allometric scaling. *PLoS ONE*. (2011) 6:e22732. doi: 10.1371/journal.pone.0022732
- 105. Moyen NE, Ganio MS, Wiersma LD, Kavouras SA, Gray M, McDermott BP, et al. Hydration status affects mood state and pain sensation during ultra-endurance cycling. J Sports Sci. (2015) 33:1962–9. doi: 10.1080/02640414.2015.1021275
- 106. Horowitz M, Samueloff S. Plasma water shifts during thermal dehydration. J Appl Physiol Respir Environ Exerc Physiol. (1979) 47:738–44. doi: 10.1152/jappl.1979.47.4.738
- 107. Stefanaki C, Pervanidou P, Boschiero D, Chrousos GP. Chronic stress and body composition disorders: implications for health and disease. *Hormones*. (2018) 17:33–43. doi: 10.1007/s42000-018-0023-7
- Ritchie RF, Ledue TB, Craig WY. Patient hydration: a major source of laboratory uncertainty. *Clin Chem Lab Med.* (2007) 45:158–66. doi: 10.1515/CCLM.2007.052
- Murck H, Schussler P, Steiger A. Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. *Pharmacopsychiatry*. (2012) 45:83–95. doi: 10.1055/s-0031-1291346

- William R, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an endocrine society position statement. *Clin Endocrinol Metabol.* (2013) 98:1376–87. doi: 10.1210/jc.201 2-3780
- 111. Fiers T, Casetta B, Bernaert B, Vandersypt E, Debock M, Kaufman JM. Development of a highly sensitive method for the quantification of estrone and estradiol in serum by liquid chromatography tandem mass spectrometry without derivatization. J Chromatogr B Analyt Technol Biomed Life Sci. (2012) 893-4:57-62. doi: 10.1016/j.jchromb.2012. 02.034
- 112. Stanczyk FZ, Jurow J, Hsing AW. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. *Cancer Epidemiol Biomarkers Prev.* (2010) 19:903–6. doi: 10.1158/1055-9965.EPI-10-0081
- 113. Dorgan JF, Fears TR, McMahon RP, Friedman LA, Patterson BH, Greenhut SF. Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry. *Steroids*. (2002) 67:151–8. doi: 10.1016/S0039-128X(01)00147-7
- 114. Christina W, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metabol. (2004) 89:534–43. doi: 10.1210/jc.2003-031287
- 115. Huhtaniemi IT, Tajar A, Lee DM, O'Neill TW, Finn JD, Bartfai G, et al. Comparison of serum testosterone and estradiol measurements in 3174 European menusing platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. *Eur J Endocrinol.* (2012) 166:983– 91. doi: 10.1530/EJE-11-1051

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor is currently co-organizing a Research Topic with one of the authors FC and CK, and confirms the absence of any other collaboration.

Copyright © 2019 Cadegiani and Kater. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.